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ABSTRACT
Hemodynamic stress and neurohumoral signaling are common causes of
cardiac hypertrophy. These extrinsic stress stimuli typically act on GPCR and
induce a cascade of signal transduction to re-program terminally differentiated
myocytes to grow in length or width. The compensatory hypertrophic response
can enhance cardiac output briefly due to increased work load. However,
prolonged stress results in maladaptive changes in the heart and gradually
deteriorates ventricular function to supply blood throughout the body. Sustained
hypertrophic signaling can also progress toward heart failure.
My dissertation research focuses on the hypertrophic signaling in adult
cardiac myocytes in response to neurohumoral stimuli, ET-1 and PE. In
particular, I am interested in the spatiotemporal activation of PKD and its
functional role in regulation of HDAC5 translocation. HDAC5 is a transcriptional
repressor whose dynamic shuttling between the nucleus and the cytosol
determines the outcome of transcriptional control for MEF2-dependent genes. I
use a combination of biochemical approach with fluorescence imaging
techniques to study the regulation of epigenetic re-programming mediated by
PKD and HDAC5 in adult cardiac myocytes during hypertrophy and heart failure.
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CHAPTER 1
INTRODUCTION
1. Cardiac Physiology and Overview
Anatomy of the Heart
The human heart plays a central role in the circulatory system to pump
and supply oxygenated blood to the organs in our body. On average, the heart
beats about 100,000 times a day, pumping approximately 2,000 gallons
(equivalent of 7,571 liters) of blood. The heart is situated in the middle of the
chest between two lungs, and it is surrounded by a double-layered membrane,
called the pericardium. The heart has four chambers and is divided into the left
and right side by the separation of the septum. The upper chambers are named
the atria and the bottom chambers are called the ventricles. The ventricles are
anatomically structured to have thicker muscular walls than the atria due to their
contractile role in ejecting the blood from the heart. In particular, the left
ventricular wall is the thickest as demanded by its role in delivering the blood to
the peripheral organs.
There are four valves that separate the atria from the ventricles and the
ventricles from the two major arteries connected to the heart. The right side of
the heart contains the tricuspid valve, located between the right atrium and the
right ventricle. The pulmonary valve separates the right ventricle from the
1
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pulmonary artery. The mitral (bicuspid) valve keeps the left atrium apart from the
left ventricle while the aortic valve separates the left ventricle from the aorta. The
anatomy of the heart is illustrated in Figure 1.
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Figure 1. Anatomy of the heart. The heart is divided into 4 chambers, namely
the right atrium and right ventricle along with the left atrium and right ventricle.
The deoxygenated blood is shown in blue while the oxygenated blood is shown
in

red.

The

image

was

taken

from

Texas

Heart

www.texasheartinstitute.org/HIC/Anatomy/anatomy2.cfm.

Institute

website:
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Function of the Heart
The function of the heart serves to pump blood throughout the body and
keeps a constant flow of our circulatory system. More specifically, the heart
pumps the deoxygenated blood into the pulmonary artery from the right ventricle,
and the oxygenated blood into the aorta from the left ventricle respectively. The
heart also receives the deoxygenated blood from the superior vena cava into the
right atrium. The venous blood then flows through the right atrium into right
ventricle and the pulmonary artery to be delivered to the lungs. Oxygenation of
the venous blood occurs at the lungs. The oxygenated blood then returns back to
left atrium via the pulmonary veins, and subsequently enters the left ventricle to
be pumped throughout the body via the aorta.

Electrical System of the Heart
In order to function as the pump of the circulatory system, the heart is an
organ that has intrinsic conduction properties to synchronize the beating of
cardiac myocytes to pump blood effectively. The synchronization of the
conduction system of the heart is of particular importance since it controls every
electrical activity of the heart. Consequently, arrhythmia or irregular heart beat
may occur when the conduction system is perturbed in anyway.
The electrical impulse originates at the sinoatrial (SA) node located on the
wall of right atrium. The SA node is also termed the “pacemaker” of the heart
because of its inherent ability to trigger electrical impulses. Each electrical

5
impulse is then transmitted to the atrioventricular (AV) node via special
conductive tissue of the heart. In case the SA node becomes unavailable or
unable to produce electrical impulses, the AV node can replace the function of
the SA node to generate electrical signals. The AV node is positioned between
the right atrium and the right ventricle. It transmits the electrical impulse onto the
Bundle of His, which divides into right and left bundle branch to allow conduction
of the right and left ventricles respectively. The two bundle branches then
connect to the Purkinje fibers, which innervate the right and left ventricular walls
to conduct electrical events. The conduction system of the heart is illustrated in
Figure 2.
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Figure 2. Electrical System of the Heart. The diagram illustrates the
conduction pathways of the electrical impulse throughout the heart. Electrical
impulses are transmitted in this order to synchronize the electrical activity of the
myocytes of the heart: SA node  AV node  Bundle of His  Purkinje fibers.
Image was taken from: http://mdmedicine.wordpress.com/2011/04/24/heartconduction-system/.
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2.

Cardiovascular Disease

Heart disease is the leading cause of death in United States. Most recent
statistics from Center for Diseases Control and Prevention indicated that there
were over 616,000 people died of heart disease in 2008, and heart disease
caused >50% of all death in United States. In general, heart disease is used to
describe many conditions or problems triggered by small plague builds up in the
wall of the arteries creating difficulties for blood flow. This condition typically
increases risks for a heart attack or stroke. There are several risk factors
contributing to heart diseases, such as high cholesterol, diabetes, high blood
pressure, obesity, smoking and inactivity. The American Heart Association
estimates that 81 million Americans suffer from one or more forms of
cardiovascular diseases. Therefore, we have a huge demand for basic
cardiovascular research to understand the cellular mechanism of heart disease
and design suitable therapeutics for these patients.

3.

Cardiac Hypertrophy

As mentioned previously, the heart has remarkable intrinsic adaptive
properties to adjust to a wide range of stress stimuli to maintain its contractile
function. When the heart is subject to prolonged stress or hindrance in electrical
activity, the organ undergoes a remodeling process in an attempt to compensate
for its increased work load. The remodeling process results in the enlargement of
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the heart, also termed “hypertrophy”. Hypertrophy can be defined as myocyte
growth in length or width to increase cardiac function to pump blood throughout
the body. The increase in myocyte length and width may or may not be uniform,
and are categorized into eccentric hypertrophy or concentric hypertrophy.
Eccentric hypertrophy is characterized by homogenous cardiac growth
response that is associated with a similar increase in ventricular wall thickness,
septum and chamber dimensions. This condition is typically accompanied by
more prominent increase in myocyte length than the increase in myocyte width.
Conversely, concentric hypertrophy is characterized by cardiac growth resulting
thickening of ventricular walls and septum without any net change in chamber
volume. There is more growth in myocyte width than length in concentric
hypertrophy.
Hypertrophy can be further separated into physiological hypertrophy and
pathological hypertrophy. Physiological hypertrophy is usually observed in
athletes and pregnant women who demand a higher amount of oxygenated blood
to be pumped throughout the body due to exercise or bearing a baby. This type
of hypertrophy is beneficial and can compensate for the increased work load by
enhancing myocyte growth to preserve cardiac function (Heineke and Molkentin,
2006). In contrast, pathological hypertrophy is characterized by enhanced
myocyte growth with reduced cardiac performance and results in heart failure
over time. Pathological hypertrophy typically develops as a response to excess
hemodynamic work load, and it can be induced by numerous stimuli, such as
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biomechanical stress, stretch-sensitive mechanism or neurohumoral signaling via
the release of cytokines, growth factors and hormones.
The objective of my dissertation work is focused on understanding the
neurohumoral signaling pathway triggering pathological hypertrophy and heart
failure in adult cardiac myocytes. The first evidence of hypertrophic responses
inducible by neurohumoral stimulus was identified by Paul Simpson in cultured
neonatal myocyotes (Simpson, 1983). Others then soon follow to examine the
possibility of neurohumoral stimuli to induce characteristic changes in kinase
activation and cardiac gene expression (Sadoshima and Izumo, 1993; Shubeita
et al., 1990). To date, neurohumoral signaling represents a common mechanism
of inducing cardiac hypertrophy in both neonatal and adult myocytes.
Nevertheless, due to the nature of neurohumoral signaling being G-protein
coupled receptors, the corresponding signaling network is inherently complex
and agonist-specific.

4.

G-Protein Coupled Receptor Signaling and Hypertrophy

As mentioned previously, neurohumoral signaling is one of the
mechanisms that can induce cardiac hypertrophy. Most neurohumoral molecules
or agonists act on their receptors, which are typically coupled to heterotrimeric
guanine-nucleotide-binding regulatory proteins (G proteins) to mediate a cascade
of intracellular response. These agonist receptors consist of the largest class of
drug targets and are called G-protein coupled receptors (GPCR). GPCR family
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has highly conserved seven transmembrane structure linked to the G-proteins via
its intracellular domains. GPCR signaling is characterized by the action of ligand
binding to its receptor, causing a conformational change of the associated
heterotrimeric G-proteins. Upon receptor activation, the G subunit typically
dissociates from the G subunits and targets its downstream effector to initiate
intracellular signaling pathway. The G subunits can also target their own
substrates to result in divergent signaling in parallel. This type of cascade
signaling orchestrates a powerful amplification of original extracellular signal to
guarantee a biological response. GPCR is coupled into 3 major G-protein
signaling families, including Gs, Gi, and Gq/G11. Each subfamily has a hallmark
intracellular signaling pathway once the heterotrimeric G proteins are activated
upon receptor stimulation. Rockman et al. has summarized a table of important
GPCR and their association with intracellular G-protein signaling (Rockman et
al., 2002).
For example, Gs activation stimulates activation of adenylyl cyclase (AC)
and triggers the production of cyclic adenosine monophosphate (cAMP) from
adenosine triphosphate (ATP) to activate downstream effectors, such as protein
kinase A (PKA) or exchange protein activated by cAMP (EPAC). In contrast, Gi
activation can turn on phosphodiesterases (PDE), which break down cAMP
molecules to terminate further cAMP signaling, forming a negative feedback loop.
The action of Gs signaling is antagonized by Gi and this prevents any feed
forward signaling mechanism.

Gq/G11
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activation is paired with activation of phospholipase C (PLC) to

create two important intracellular 2nd messengers, inositol 1,4,5-trisphosphate
(IP3) and diacylglycerols (DAG). IP3 and DAG can further activate several
downstream targets. IP3 production elicits calcium (Ca2+) release from
intracellular IP3 stores, such as the endoplasmic reticulum (ER), the sarcoplasmic
reticulum (SR) or the nuclear envelope. With Ca2+ being an universal 2nd
messenger, intracellular Ca2+ release in turn triggers several cellular effectors,
such as calcineurin, Ca2+-calmodulin-dependent protein kinase II (CaMKII) and
nuclear factor of activated T-cell (NFAT). The family of NFAT transcription factors
are critical mediators of pathological hypertrophy. In parallel, DAG can activate
its targets, for instance, the classical and novel protein kinase C (PKC) isoforms.
These isoforms possess inherent DAG-binding domains which are recruited to
the plasma membrane or to microdomains near the DAG pools facilitating their
activation via cross-phosphorylation.
Many adaptive mechanisms have evolved from our biology to curtail the
GPCR signal. The first is known as receptor “desensitization” whereby receptor
responsiveness is attenuated even in the presence of continuous agonist
stimulation. The receptor desensitization is categorized into homologous or
heterologous desensitization depending on whether the process is initiated by
the same ligand receptor or another ligand receptor. Alternatively, the receptors
can also be “downregulated” to minimize the triggered physiological response.
The downregulation of GPCR can be achieved by a decrease in receptor
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synthesis or an increase in receptor degradation. The receptor desensitization
and downregulation mechanisms are typically mediated through modification of
the receptors by receptor kinases, such as G-protein receptor kinase (GRK)
family. Lastly, the GPCR signal can also be terminated by uncoupling of the
receptor from its associating G-proteins.

GPCR Signaling and Hypertrophy
Almost all the GPCR linked to Gq signaling are capable of triggering
cardiac hypertrophy. The most common and most studied GPCR receptor types
in the heart include the adrenergic receptors ( and  subtypes) for
norepinephrine (NE) and phenylephrine (PE), the endothelin (ET) receptors
(ETAR and ETBR) for endothelin-1 (ET-1) and the angiotensin-1 receptor for
angiotensin II. A body of published works has supported the notion that GPCR
activation associated with Gq signaling via different surface receptors can
sufficiently induce cardiac hypertrophy. For instance, -AR activation is reported
to trigger hypertrophy in response to NE stimulation and pressure overload
(Bishopric et al., 1987; Long et al., 1989; O'Connell et al., 2003; O'Connell et al.,
2006; Simpson, 1983). Similarly, endothelin receptors are also involved in
hypertrophic response induced by multitude stress stimuli (Bossuyt et al., 2011;
Higazi et al., 2009; Huang et al., 2011; Mueller et al., 2011; Shubeita et al.,
1990).

My dissertation

research

primarily focuses on the intracellular

hypertrophic signaling induced by Gq-agonists, ET-1 and PE in isolated adult
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cardiac myocytes. More pertinently, I examine how these two Gq-signaling
pathways diverge from each other to play a regulatory role in epigenetic control
of cardiac remodeling process.

5.

-Adrenergic Signaling and Hypertrophy

Background


-adrenergic activation represents one of the major pathways to increase

cardiac performance during sympathetic stimulation or acute stress signaling.
There are three different -adrenergic receptors (-AR) identified in humans (1,
2 and 3). They share approximately 60% amino acid sequence homology in the
transmembrane region where it binds ligands, the catecholamines. 1-AR and 2AR are the dominant receptor types expressed in the heart, and their relative
distribution is 75% vs. 25% respectively (Lohse et al., 2003; Rockman et al.,
1997). They are also responsible for the majority cardiac adrenergic response
during endogenous catecholamine signaling by norepinephrine and epinephrine.
The functional role of 1-AR is widely accepted to be coupled to Gs signaling,
which in turn triggers cAMP production via activation of AC. The classical cAMP
signaling effector is PKA, and EPAC is recently identified to be another novel
effector of cAMP signaling (Berthouze et al., 2011; Dodge-Kafka et al., 2005;
Pereira et al., 2007; Pereira et al., 2012). 1-AR activation increases cardiac
performance by improving cardiac contractility, increasing heart rate and
lusitropy. 2-AR are coupled to both Gs and Gi signaling pathways, and its
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functional role is more complex than 1-AR. It has been shown that 2-AR are
coupled to AC with similar affinity, yet they exhibit minor functional role in
regulation of contractility (Xiang, 2011; Zhao et al., 2011). Coupling of 2-AR to
Gi has been indicated to gradually become more significant in failing animal and
human cardiac myocytes (Gong et al., 2002; Xiao et al., 1999a; Xiao et al.,
1999b).


3-AR are initially found to be present only in adipose tissues, however,

recent research shows that they are also expressed on the nuclear membranes
of cardiac myocytes (Boivin et al., 2006; Vaniotis et al., 2011). Unfortunately,
their functional role in the heart remains poorly defined as their expression
density is dominated by the presence of 1-AR and 2-AR. They are not
speculated to participate in the regulation of cardiac contractility because
transgenic double knockout mice for both 1-AR and 2-AR exhibit significantly
reduced contractile function despite the presence of 3-AR (Devic et al., 2001). It
is therefore evident that these -AR subtypes have non-redundant functional
roles in cardiac myocytes.

Cardiac Distribution and Function of 1 vs.2
Recent efforts have been devoted to examine the cellular distribution of
1-AR vs 2-AR in cardiac myocytes with development of new molecular tools in
imaging and fluorescence resonance energy transfer (FRET) based biosensor to
detect cAMP production (Nikolaev et al., 2006; Nikolaev et al., 2010). The
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findings suggest that 1-AR are distributed to both the T-tubules and cell surface
while 2-AR are localized mostly at the T-tubular region. The different cellular
distributions of these two receptors reflect the corresponding divergent cAMP
signaling patterns. 1-AR activation induced cAMP signaling is reported to be
more global and propagates throughout the entire myocyte. Conversely,
activation of 2-AR results in more local cAMP signaling that is confined to the Ttubules (Nikolaev et al., 2006; Nikolaev et al., 2010).
The compartmentalized cAMP signaling of 2-AR activation is achieved by
local cAMP buffering via association of PKA activity and PDE activation (AbiGerges et al., 2009; Fischmeister et al., 2006; Leroy et al., 2008; Nikolaev et al.,
2010). In addition, the family of scaffolding proteins called the A Kinase
Anchoring Protein (AKAP) also contributes to the spatiotemporal cAMP signaling
by associating PKA with PDE in various compartments within cardiac myocytes
(Appert-Collin et al., 2006; Appert-Collin et al., 2007; Diviani et al., 2006; Hall and
Lefkowitz, 2002). PDE are the enzymes which degrade cAMP molecules to
impose a negative feedback loop for cAMP signaling. The divergent cAMP
signaling pathways induced by these two receptors represent an elegant intrinsic
regulation of spatiotemporal cAMP signaling in healthy myocytes.

Nuclear Signaling of -AR
-AR are known prototypical GPCRs, and the classical paradigm of these
receptor signaling is confined only at the plasma membrane. Increasing amount
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of studies is exploring the notion of GPCR signaling at the nuclear membrane. In
particular, 1-AR and 3-AR (but not 2-AR) are also found to localize at the
nuclear membrane in rat and mouse adult myocytes (Boivin et al., 2006; Boivin et
al., 2008). One of the nuclear functions of 1-AR and 3-AR is to trigger de novo
transcription, and this is achieved in part via being differentially coupled to Gs
and Gi signaling pathways in isolated cardiac nuclei. The findings that
ribosomal RNA and mRNA synthesis can be modulated by -AR stimulation
further support the notion that -AR signaling plays a role in nuclear signaling
(Vaniotis et al., 2011). However, future work on the functional role of -AR
signaling in the nucleus remains to be continued to explore further understanding
of -AR regulation on gene modification in cardiac myocytes.

-AR Signaling in Hypertrophy and Heart Failure
Chronic catecholamine stimulation is well known to trigger hypertrophy
and heart failure (Chidsey et al., 1963; Lefkowitz et al., 2000; Lohse et al., 2003),
thus emphasizes the importance of -AR activation and its ability to regulate
cardiac disease. Moreover, reduced -AR response and -AR downregulation
are leading characteristics for deteriorating cardiac function. To date, -blockers
are the most effective treatment for chronic heart failure even though its
mechanism of action remains paradoxical (Braunwald and Bristow, 2000;
Bristow, 2000; Bristow, 2011; Kubon et al., 2011).
Even though both 1-AR and 2-AR respond to adrenergic stimulation,
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selective activation of either receptor type exhibits differential physiological
responses. For instance, transgenic overexpression of 1-AR results in
progressive cardiac hypertrophy and heart failure (Bisognano et al., 2000;
Engelhardt et al., 1999), while2-AR overexpression in mice produces enhanced
myocardial function (Milano et al., 1994). Furthermore, 2-AR knockout mice
develop more severe cardiac hypertrophy in response to pressure overload by
transverse aortic constriction (TAC) compared to 1-AR deletion knockout (Zhao
et al., 2011). The two -AR subtypes also show opposing effect on apoptosis and
cell survival in cardiac moycytes (Communal et al., 1999; Zhu et al., 2003; Zhu et
al., 2001). Overall, the 2-AR signaling appears to be more cardioprotective than
1-AR activation. However, the implicit differential coupling of both subtypes to
Gs or Gi does not sufficiently explain the opposing physiological responses
produced by selective receptor stimulation.
As mentioned previously, 1-AR activation stimulates Gs signaling to
activate PKA as its major effector to phosphorylate numerous intracellular
targets. For example, active PKA is identified to phosphorylate several key
proteins involved in excitation-contraction coupling (ECC), such as the L-type
Ca2+ channel, the ryanodine receptor and phospholamban (PLB) (Bers, 2002;
Hagemann and Xiao, 2002; Valdivia et al., 1995; Xiao et al., 2007; Zhou et al.,
2009). However, recent studies on the time-dependence activation of 1-AR
show that additional signaling pathways can be evoked under sustained 1-AR
stimulation. Indeed, sustained 1-AR stimulation results in a shift from PKA
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activation to CaMKII activation, and active CaMKII is involved in cardiac
apoptosis, fetal gene activation and phosphorylating PLB at threnonine 17 site
(different from the serine 16 phosphorylation by PKA) (Sucharov et al., 2006;
Wang et al., 2004; Zhu et al., 2001).
It is well documented that 1-AR are desensitized and downregulated by
internalization, resulting in reduced adrenergic response, a hallmark of
deteriorating cardiac function and heart failure (Bristow et al., 1982; Brodde,
1996; Choi and Rockman, 1999; Fowler et al., 1986; Lohse et al., 2003). The
desensitization of -AR during hypertrophy is caused by increased -adrenergic
receptor kinase (ARK), which phosphorylates the -AR to initiate their
internalization (Choi et al., 1997; Ungerer et al., 1993). In parallel, the expression
and activity of PDE are decreased during hypertrophy, thus prolonging the cAMP
signal and activity of ARK to desensitize -AR (Abi-Gerges et al., 2009; Senzaki
et al., 2001; Takahashi et al., 2002).
In contrast to the downregulation of 1-AR, there is no significant reduction
of 2-AR during heart failure (Engelhardt et al., 1996; Kiuchi et al., 1993). Hence,
the downregulation of 1-AR could substantially alter the relative distribution of 
receptors in the heart. Moreover, research in heart failure myocytes
demonstrates that 2-AR mediated cAMP signaling is altered to resemble the 1AR induced response, where cAMP signaling propagates throughout the
myocyte and is no longer confined to local signaling (Nikolaev et al., 2006;
Nikolaev et al., 2010). This is attributed partially by loss of T-tubulation in heart
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failure myocytes. This causes the re-distribution of 2-AR within the myocyte and
represents a mechanism to exacerbate heart failure.

6.

Protein Kinase D in Hypertrophy

Background
Protein kinase D (PKD) was initially identified as PKC mu (PKC), as a member
of the PKC family, by two different groups (Johannes et al., 1994; Valverde et al.,
1994). However, it was subsequently characterized to be part of the CaMKII
superfamily based on its catalytic function and substrate specificity (Manning et
al., 2002; McKinsey, 2007). PKD is a serine/threonine kinase consisting of 918
amino acids. To date, three different isoforms (PKD 1, 2 and 3) have been
reported in various cell types (Avkiran et al., 2008; Rozengurt, 2011). All three
isoforms are highly conserved in their sequence homology and function (Avkiran
et al., 2008; Wang, 2006). PKD1 is the isoform ubiquitously expressed
throughout different tissues and the dominant isoform expressed in the heart. In
general, PKD is emerging as a critical signal transducer of extrinsic stress signal
to intracellular processes due to its implication in multiple cellular functions
ranging from cell proliferation (Bollag et al., 2004; Ernest Dodd et al., 2005; Liu et
al., 2007), immune signaling (Matthews et al., 2006; Spitaler et al., 2006),
apoptosis (Johannes et al., 1998; Trauzold et al., 2003), Golgi formation
(Ghanekar and Lowe, 2005), cancer regulation (Eiseler et al., 2009; Jaggi et al.,
2007) to cardiac hypertrophy via transcriptional regulation of HDAC5 (Bossuyt et
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al., 2011; Bossuyt et al., 2008; Harrison et al., 2006; Vega et al., 2004) and
cardiac contractile function via altering its Ca2+ sensitivity (Cuello et al., 2007;
Goodall et al., 2010; Haworth et al., 2004).

PKD Function
Like many other cellular kinases, PKD functions as a kinase that
phosphorylates at the serine and threonine residues of its target substrates. PKD
requires a particular substrate sequence for its targets. Specifically, relative to its
targeted serine/threonine residue, it prefers an aliphatic amino acid at the -5
position and a basic amino acid (especially arginine) at the -3 position (Avkiran et
al., 2008). Studies have suggested that PKD is a highly mobile kinase in many
cellular compartments, such as cytosol, Golgi, mitochondria and the nucleus.
Some of its targets include cardiac troponin I, histone deacetylase 5 (HDAC5), cjun and cAMP-response element binding protein (Avkiran et al., 2008; Rozengurt,
2011; Wang, 2006).
With a diverse group of target substrates, PKD is involved in numerous
cellular functions. With regards to its cardiac function, PKD has been reported to
regulate hypertrophic signaling via its role in phosphorylating transcriptional
repressor, HDAC5 (Bossuyt et al., 2011; Bossuyt et al., 2008; Harrison et al.,
2006; Vega et al., 2004), and to modulate myocyte contractile function via its role
in altering Ca2+ sensitivity of cardiac troponin I (Cuello et al., 2007; Goodall et al.,
2010; Haworth et al., 2004). The importance of PKD activity during hypertrophy
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has also been demonstrated in the several ways. For example, constitutively
active PKD induces cardiac hypertrophic in transgenic mice (Harrison et al.,
2006), and cardiac specific deletion of PKD1 in knockout mice display a reduced
hypertrophic heart in response to pressure overload (Fielitz et al., 2008).
Moreover, PKD expression and activity both are found to be increased in failing
human and animal myocardium (Bossuyt et al., 2008; Harrison et al., 2006),
validating its regulatory role in cardiac hypertrophy.
Specifically, my work focuses on the functional role of PKD in the heart. I
will examine the role of PKD activation and its functional effects on hypertrophic
signaling in response to neurohumoral stimuli. Understanding the underlying
cellular mechanism of how PKD is activated and its function during stress
stimulation in adult cardiac myocytes will strengthen its potential as a future
therapeutic for cardiac disease treatment.

PKD Structural Domains
The structure of this kinase includes the N-terminal inhibitory region with
two cysteine-rich domains, an internal pleckstrin homology (PH) domain and
catalytic domain near the C-terminus (Avkiran et al., 2008; Fu and Rubin, 2011;
Wang, 2006). The N-terminal region of PKD exhibits autoinhibitory effect on its
catalytic activity since various mutations and deletions of this region can activate
PKD to different degrees (Iglesias et al., 1998a; Iglesias et al., 1998b). PKD can
be activated by several extrinsic stimuli, such as growth factors, GPCR agonists,

22
B cell/T cell receptors and phorbol esters (Fu and Rubin, 2011; Rozengurt, 2011;
Rozengurt et al., 2005). It is involved in several important cellular functions from
proliferation, differentiation, cell motility to protein transport, membrane
trafficking, apoptosis and cell survival. An illustration of the PKD domains is
depicted in Figure 3.
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Figure 3. Schematic diagram of PKD1 domains.

The C1 domains of PKD are similar to those found in the PKC family and
are designated as C1a and C1b domains. These tandem cysteine-rich domains
impart reverse membrane translocation function via their ability to bind to diverse
phospholipids (Colon-Gonzalez and Kazanietz, 2006; Gallegos and Newton,
2008; Valverde et al., 1994). Nevertheless, the relative lipid-binding affinity of
these two C1 domains remains to be clarified. Some suggest that the C1a and
C1b domains display equivalent binding properties (Irie et al., 1999) while other
report disparate binding affinities (Iglesias et al., 1998a; Oancea et al., 2003;
Wang et al., 2003). In addition, these two motifs contribute to the autoinhibitory
effect of PKD activity, and such autoinhibition can be relieved by C1a and C1b
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binding to intracellular DAG or phorbol ester. The tandem domains also display
dissimilar characteristics in binding DAG and phorbol ester across all three
isoforms. Jun Chen et al. characterizes individual C1a, C1b or C1a-C1b domain
of PKD in vitro. Their findings suggest that C1a confers the majority of the DAGbinding ability. It should be noted that these two motifs have differential selectivity
and ligand-binding affinities for DAG and phorbol ester on an individual basis.
Accordingly, intact C1a and C1b domains together are sensitive to structural
context to modulate their selectivity and ligand-binding affinities (Chen et al.,
2008).
The PH domain is commonly found in proteins that mediate signal
transduction or cellular trafficking (Liao and Hung, 2010; Mashanov et al., 2004).
This domain is typically found to bind to phosphoinositol phospholipids. However,
the role of PH domain within PKD to bind phosphoinositide is unclear since it
shows low affinity for phospholipids (Wang et al., 2003). Thus far, the role of PH
domain of PKD is reported to be autoinhibitory based on the evidence that
tyrosine phosphorylation, protein interaction with itself or G or activation loop
phosphorylation can trigger PKD activation (Jamora et al., 1999; Storz et al.,
2003; Waldron and Rozengurt, 2003).
At its C-terminus, the last six amino acid residues of PKD1 and PKD2
makes up a motif that can bind to PSD-95, Disc large and ZO-1 (PDZ) domain,
which is known to mediate protein interaction. This domain typically plays a part
in protein targeting and complex assembly (Hung and Sheng, 2002). Its
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functional role is achieved by interacting with the PDZ domain of other proteins or
its PDZ recognition sequences. For example, the C-terminal amino acid
sequence ERVSIL of PKD1 and ERISVL of PKD2 are PDZ-binding motifs
(Sanchez-Ruiloba et al., 2006), which are absent in PKD3. This allows PKD1 and
PKD2 to form potential protein-protein interactions with numerous cellular
proteins with PDZ domains or PDZ-binding sequence although such interaction is
largely unknown.
Accordingly, the S916 of PKD1 and S873 of PKD2 are at the -2 position
relative to the PDZ-binding residue, thus phosphorylation at these two serines
has significant impact in determining the intracellular translocation and
localization of PKD1 and PKD2 via interaction with other PDZ domains. For
instance, Kunkel et al. identified that PKD binds to the Na/H exchanger
regulatory factor 1 (NHERF1) complex via PDZ domain interaction upon PdBu
stimulation (Kunkel et al., 2009). The study indicates that PKD activation at its
autophosphorylation site enhances its association with another molecular
complex intracellularly. This adds another mechanism to modulate PKD activity
via possibly tethering to any scaffolding complex, such as the NHERF1.
Therefore, future findings of PKD interaction with other proteins via PDZ domain
can provide useful information regarding its activation in the heart.

PKD Phosphorylation and Activation
In general, basal cellular PKD activity remains low due to its regulatory
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autoinhibitory mechanism imposed by the N-terminal region. The canonical
activation pathway of PKD is via a PKC-dependent mechanism (Rey et al., 2004;
Waldron and Rozengurt, 2003; Wang, 2006) although a PKC-independent
mechanism has also been described (Jacamo et al., 2008; Sinnett-Smith et al.,
2009). The PKC-dependent mechanism triggers membrane recruitment of PKD
along with upstream PKC isoforms attributed to DAG production and DAGbinding via C1a and C1b domains. Active PKC then cross-phosphorylate PKD
near the plasma membrane at its serine 744 and serine 748 (SS744/748) sites
within the catalytic domain of PKD. Consequently, SS744/748 phosphorylation of
PKD relieves the autoinhibition from the regulatory N-terminal region, and the
partially active PKD autophosphorylate itself at serine 916 (S916) residue. The
fully active PKD subsequently undergoes reverse translocation to intracellular
compartments to phosphorylate its substrate targets.

The predominant PKC

involved in this canonical PKD activation are the Ca 2+-independent novel PKC
isoforms (, , and ) (Brandlin et al., 2002a; Brandlin et al., 2002b; Rey et al.,
2004; Waldron and Rozengurt, 2003).
Conversely, the PKC-independent mechanism of PKD activation is also
reported.

This

type

of

activation

is

proposed

to

occur

by

distinct

autophosphorylation at the activation loop (Jacamo et al., 2008; Sinnett-Smith et
al., 2009). The PKC-independent mechanism of PKD activation in cardiac
myocytes remains to be explored. Lastly, there is also indirect evidence in
immortal cell lines suggesting possible Ca2+-dependent activation of PKD. The
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study reported PKD activity upon addition of thapsigargin, an inhibitor of
sarcoplasmic/endoplasmic reticulum Ca2+-ATPase pump and ionomyocin, a Ca2+
ionophore. CaMKII inhibition by KN93 confirmed that the Ca 2+-induced response
was specific to PKD and not CaMKII activation (Kunkel et al., 2007). The findings
point to an interesting mechanism of PKD regulation by intracellular Ca 2+,
however, further studies are required to dissect the nature and pathway of such
regulation.
There is a significant decrease in PKD expression in the heart during
development from neonates to adult myocytes (Haworth et al., 2000). While the
studies above have uncovered certain PKD activation mechanisms, more work
remains to be done in investigating the PKD activation in adult cardiac myocytes.
In particular, my research will focus on dissecting the spatiotemporal PKD
activation during the hypertrophic signaling of adult cardiac myocytes in response
to neurohumoral stimulation.

7.

Histone Deacetylase 5 in Hypertrophy

Background
Histone deacetylases (HDACs) are transcriptional repressors crucial to the
regulation of gene transcription in many cell types (Haberland et al., 2009;
Johnson and Turner, 1999; Martin et al., 2007; Martin et al., 2009). HDACs can
preclude access to transcriptional factors via chromatin condensation and
consequently suppress transcriptional activation of its target genes (Backs and
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Olson, 2006; Bush and McKinsey, 2009). As epigenetic regulators, HDACs are
involved in multitude of cellular processes, such as proliferation, cardiac function,
bone formation, vasculature formation and myogenesis (Haberland et al., 2009;
Martin et al., 2009; Yang and Gregoire, 2005). Due to their role as essential
modulators of gene transcription or repression, HDACs have many implications
in physiology and disease development. Consequently, recent effort has been
focused on inhibition of HDACs function and their potential use as clinical
therapies for treating a wide range of disease (Haberland et al., 2009; McKinsey,
2011; McKinsey, 2012; Stimson et al., 2009).
To date, with 18 identified mammalian isoforms, the HDAC superfamily is
divided into 4 distinct classes (class I, II, III and IV) with a relatively conserved
catalytic domain (Bertos et al., 2001; Yang and Gregoire, 2005). Compared to
other subtypes, class II HDACs (4, 5, 6, 7, 9 and 10) exhibit tissue-specificity with
predominant expression in skeletal muscles, heart, brain and T-cells while class I
and III are found more ubiquitously expressed in other cell types (McKinsey and
Olson, 2005; Parra and Verdin, 2010; Yang and Gregoire, 2005). Additionally,
class II HDACs are further grouped into class IIa (4, 5, 7 and 9) and IIb (6 and
10) and its members are characterized by a long N-terminal extension available
for interactions with other transcriptional activators and co-repressors (Haberland
et al., 2009). Lastly, class II HDACs are signal-dependent repressors, which can
be subject to phosphorylation at particular residues in response to agonist
stimulations (Parra and Verdin, 2010).
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HDAC5 Function
The functional role of HDACs is to remove acetyl groups from histone
tails, hence condensing the chromatin structure. Their function opposes the
action of histone acetyl transferases (HAT), which results in relaxation of the
chromatin structure by adding acetylation and encouraging transcriptional activity
(Backs and Olson, 2006; Bertos et al., 2001; McKinsey and Olson, 2005). Many
in vivo studies have examined the functional role of HDAC5 in the heart and its
consequent stress-induced exacerbated cardiac hypertrophy in knockout mice
with a loss-of-function phenotype (Chang et al., 2004; Haberland et al., 2009;
Kee and Kook, 2011), highlighting the importance of its cellular localization and
function in regulating cardiac physiology and pathology. Specifically, fundamental
regulation of HDAC5 is crucial to cardiac remodeling and hypertrophy at the
cellular level, where activation of “fetal gene program” is initiated by relieving
transcriptional inhibition to activate myocyte enhancer factor 2 (MEF2) controlled
genes (Bertos et al., 2001; Calalb et al., 2009; Chang et al., 2004; Kee and Kook,
2011). Recent studies have focused on the understanding the trafficking of
HDAC5 between the nucleus and the cytoplasm as its gene repression function
is highly correlated with its localization within the cell (Harrison et al., 2010;
Harrison et al., 2004; McKinsey and Olson, 2005; Wu et al., 2006; Zhang et al.,
2002).
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HDAC5 Structural Domains
HDAC5 belongs to the class IIa family of HDACs and shares highly
conserved sequence homology with HDAC 4, 7 and 9 (Bertos et al., 2001; Martin
et al., 2007; Martin et al., 2009). While several in vivo mouse knockout studies
have demonstrated the importance of these class IIa members during
development and disease, HDAC5 is the isoform most pertinent to cardiac
pathophysiology since genetic deletion creates cardiac hypertrophy and
ventricular defects in the knockout mouse (Bush and McKinsey, 2009). Like the
rest of the class IIa members, HDAC5 contains an N-terminal MEF2-binding
domain, followed by a nuclear localization sequence (NLS) with a catalytic
deacetylase domain near the nuclear export sequence (NES) at the C-terminus.
With its inherent NLS and NES signals, the cellular localization of HDAC5 in the
nucleus or the cytosol can be altered depending on the current modification of
either signal.
There are mixed evidence supporting the catalytic activity of HDAC5 in
cardiac myocytes by itself. For example, some reports demonstrate that HDAC5
oligomerizes with HDAC4 to achieve its catalytic function to suppress gene
transcription (Backs et al., 2008). Others also observe an association of HDAC3
with HDAC5 to account for the cellular deacetylase activity of HDAC5 (Greco et
al., 2011). In contrast, transcriptional activation is also detected with nuclear
export of HDAC5, relieving transcriptional inhibition of MEF2-dependent genes
(Bossuyt et al., 2011; Bossuyt et al., 2008; Harrison et al., 2004; Lu et al., 2000a;
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Lu et al., 2000b). Therefore, the functional role of HDAC5 remains to be further
investigated in adult cardiac myocytes.

HDAC5 Phosphorylation and Regulation
Thus far, five phosphorylation sites of HDAC5 have been described to
participate during its phosphorylation-dependent nuclear export mechanism.
Compelling evidence have established that HDAC5 nucleocytoplasmic shuttling
is highly regulated by its phosphorylation at serine 259 (S259) and serine 498
(S498) to initiate its phosphorylation-dependent nuclear export via binding to 143-3 chaperone proteins and unmasking its NES signal (Kee and Kook, 2011;
McKinsey et al., 2000b; McKinsey et al., 2001). Accordingly, we and others have
reported that neurohumoral stress stimuli coupled to activation of G-protein
receptors can trigger downstream effector kinases, such as CaMKII and PKD to
phosphorylate HDAC5 at S259 and S498 to mediate its nuclear export in cardiac
myocytes (Bossuyt et al., 2011; Bossuyt et al., 2008; Ellis et al., 2003; Harrison
et al., 2010; Harrison et al., 2006; Lu et al., 2000b; McKinsey and Olson, 2005;
McKinsey et al., 2001).
Moreover, alternative phosphorylation sites of HDAC5 have also been
introduced during its phosphorylation-dependent nuclear export. For instance,
Carnegie et al. reports that serine 660 (S660) of HDAC5 is another site available
for PKA and PKD phosphorylation to trigger nuclear export (Carnegie et al.,
2008). In addition, serine 279 within the NLS region of HDAC5 was recently
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discovered to be involved in PKA-induced phosphorylation to negatively
modulate its nuclear export event (Ha et al., 2010). Threonine 292 (T292) with
the NLS of HDAC5 is reported to be phosphorylated by protein kinase C-related
kinase (PRK)-2 and PRK1 (Harrison et al., 2010).
Recent proteomics approach encourages further comprehensive study of
phosphorylation sites of HDAC5 in vivo and reports a total of 17 sites that can or
might dynamically regulate HDAC5 translocation and function (Greco et al.,
2011). These findings strongly implicate the complexity of the fundamental
regulation of HDAC5 trafficking within the cell via phosphorylation and
association with other proteins. The dynamic shuttling of HDAC5 between the
nucleus and the cytosol has been investigated due to its specific expression and
function in cardiac myocytes, yet detailed mechanism of its regulated trafficking
remains to be elucidated, especially during activation of multiple stress stimuli.

8.

Conclusion

The heart is a complex organ that is structured and designed to serve its
contractile function as the pump of the circulatory system by continuously
supplying blood throughout the body. Its intrinsic conduction properties allow the
synchronization of the electrical activity among the myocytes to produce one
contraction after the other. The heart display remarkable adaptive responses to
diverse stress stimuli in order to preserve its contractile function. When the heart
is subject to any prolonged stress or hindrance to conduct electrical activity, its
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function to eject blood will decrease over time.
These alterations to cardiac function will induce development of many
cardiac diseases. The inherent compensatory mechanism of the heart to cope
with its increased work load is by triggering myocyte growth, thus resulting in
cardiac hypertrophy. It is well established that cardiac hypertrophy produces
initial compensatory effects, but it deteriorates ventricular function over time and
typically progress toward heart failure. With cardiac hypertrophy being the
hallmark characteristic of worsening cardiac function, therefore it has become
one of the major topics for cardiovascular research for the last fifty years.
With many cell line and neonatal studies laying the ground work of
hypertrophic signaling pathways, many questions remain to be addressed in
adult cardiac myocytes. Therefore, my dissertation work aims to explore the
cellular mechanism of how hypertrophic signaling occurs in adult cardiac
myocytes in response to neurohumoral stimuli. I will focus primarily on using
fluorescence imaging techniques (confocal and FRET imaging) combined with
some biochemical approaches to investigate the roles of PKD activation and
HDAC5 translocation during hypertrophic signaling in adult cardiac myocytes.

CHAPTER 2
SPECIFIC AIMS
Aim 1: To determine the spatiotemporal activation of PKD by hypertrophic
agonist, such as ET-1 and PE, in adult cardiac myocytes.
Hypertrophic agonists, ET-1 and PE, act on GPCR and activate
phospholipase C-, which produces two important 2nd messengers, IP3 and DAG.
PKD, along with CaMKII, has been identified as important mediators for
hypertrophy and heart failure via the regulation of transcription repressor, HDAC5
(Backs et al., 2008; Harrison et al., 2010; Harrison et al., 2006; McKinsey and
Olson, 2005; Wu et al., 2006). Previous work by Bossuyt et al. showed that both
CaMKII and PKD are upregulated in both expression and activity during heart
failure (Bossuyt et al., 2008). In order to better understand the role of PKD
activation during Gq-driven hypertrophic signaling and its potential as a
therapeutic target, it is critical to examine its fundamental spatial and temporal
activation within the myocytes.
My overall hypothesis is that ET-1 and PE induce different
spatiotemporal patterns of PKD activation which may influence the role of
PKD during hypertrophic signaling. We plan to evaluate intracellular PKD
activation using multiple approaches. Since HDAC5 is a known target of PKD
33
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and its nuclear export parallels fetal gene activation in adult myocytes, we will
first measure HDAC5 nuclear export in response to ET-1 and PE stimulation. To
further investigate the role of PKD in mediating Gq-driven HDAC5 nuclear export,
we will use a number of pharmacological inhibitors (e.g Gö6976 and PKDI) to
block PKD activity prior to ET-1 or PE treatment. To date, canonical PKD
activation mechanism describes its phosphorylation by upstream PKC at S744
and S748 sites followed by PKD autophosphorylation at its S916 residue. Using
immunoblotting and phospho-specific antibodies, we will also assess the level of
its phosphorylation at S744 and S748 (PKC sites) and its auto-phosphorylation at
S916 in response to ET-1 and PE stimulation.
To test whether PKD activation by ET-1 and PE results in its translocation
within the myocyte, we will generate an adenoviral construct of wild type (WT)
PKD1-green fluorescence protein (GFP) to measure its intracellular translocation
using confocal microscopy. Specifically, we will focus on PKD translocation to the
sarcolemma, where it is postulated to be phosphorylated by upstream PKC
isoforms and to the nucleus, where it can phosphorylate and mediate HDAC5
nuclear export.
In parallel, we will also use a FRET-based sensor, D Kinase Activity
Reporter (DKAR), to measure the PKD activity in response to ET-1 and PE
treatment. The DKAR biosensor produces a decrease in FRET signal when a
conformational change occurs due to active PKD phosphorylating its pseudo
substrate peptide flanking the cyan fluorescence protein (CFP) and yellow
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fluorescence protein (YFP). After we have measured the spatial dynamics of
PKD activation in confocal translocation studies, we can assess its localized
activity using targeted DKAR, such as the sarcolemmal DKAR (DKAR-MyrP) and
nuclear DKAR (DKAR-NLS) to measure its activity near the plasma membrane
and in the nucleus respectively.
Overall, aim 1 will investigate the spatiotemporal activation of PKD in
response to hypertrophic agonist, ET-1 and PE in adult cardiac myocytes. Global
PKD activation will be assessed by its phosphorylation level at S744/S748 and at
S916, its auto-phosphorylation site. Confocal translocation study will provide
spatial dynamic data of real time PKD activation within the myocytes. Results of
FRET biosensor, DKAR, will measure its global activity during ET-1 and PE
stimulation. Specifically, we will contrast its glocal activation with its local
activation signals obtained in two particular compartments, the sarcolemma and
the nucleus, where PKD can be activated by upstream PKC and can mediate
HDAC5

nuclear

export

respectively.

Understanding

the

fundamental

spatialtemporal activation of PKD within the myocyte will improve future
therapeutic strategy in treating hypertrophy and heart failure.
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Aim 2: To examine the cross-interaction of Gq and -AR signaling in adult
cardiac myocytes at the level of HDAC5 shuttling between the nucleus and
the cytosol
Previous work from our lab (Bossuyt et al., 2011; Bossuyt et al., 2008; Wu
et al., 2006) shows that Gq-signaling triggers HDAC5 nuclear export during
hypertrophy. However, the role of PKA signaling in HDAC5 localization in adult
cardiac myocytes remains unclear. There is evidence suggesting that PKA
activation may facilitate hypertrophic signaling of PKD and HDAC5 nuclear
export (Carnegie et al., 2004; Carnegie et al., 2008) while some report that PKA
signaling exerts an anti-hypertrophic effect to inhibit HDAC5 nuclear export (Ha
et al., 2010; Sucharov et al., 2011). During hemodynamic stress, catecholamines
and neurohumoral stimuli may induce co-activation of Gq-coupled receptors and
-AR leading to cardiac remodeling.

Dynamic regulation of HDAC5, a

transcriptional repressor, is crucial during stress signaling due to its role in
epigenetic control of fetal gene markers. Little is known about its regulation
during acute and chronic -AR stimulation and its cross interaction with Gqsignaling in adult cardiac myocytes.
My overall hypothesis is that -AR signaling regulates the Gq-driven
transcriptional control at the level of HDAC5 nucleocytoplasmic shuttling in
adult cardiac myocytes. First, we will use confocal microscopy to determine
HDAC5 translocation under Gq-agonist, ET-1 and PE, and -AR/PKA activation
using isoproterenol (ISO) and forskolin. The results of -AR and PKA signaling
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on HDAC5 translocation will be compared to the previous work from our lab
where Gq-agonist mediates its nuclear export. S259/S498 residues of HDAC5
have been well characterized to be the major targets of CaMKII and PKD to
mediate its phosphorylation-dependent nuclear export. We plan to create a
mutant with alanine substitution at these two sites and test its response to AR/PKA and Gq-signaling. While the S279 site of HDAC5 has been recently
identified to be phosphorylated by PKA in vitro (Ha et al., 2010), we will generate
a non-phosphorylatable mutant (S279A) and a phosphomimetic mutant (S279D)
to test its translocation under -AR and Gq-activation.
In addition, we will also pretreat myocytes with ISO and forskolin for 20
min prior to Gq-stimulation by ET-1 or PE to examine the effect of PKA activation
on Gq-driven HDAC5 nuclear export. To complement the results of the confocal
HDAC5 translocation, we will also use western blots to determine the level of
endogenous HDAC5 S498 phosphorylation and co-immunoprecipitation (co-IP)
to probe its binding to chaperone protein, 14-3-3, under Gq-agonist treatment
alone or pre-incubation with ISO or forskolin.
To further dissect the mechanism of PKA action on hypertrophic signaling,
we will also study the effects of acute vs. chronic treatment of forskolin on Gqmediated HDAC5 nuclear export. Understanding the acute vs. chronic PKA
stimulation is important in terms of cardiac physiology regulation. Acute PKA
signaling in short term sympathetic tone, such as during exercise or fight or flight
response, can increase cardiac output without triggering transcriptional changes.
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In contrast, it is also well documented that chronic -AR signaling alters cardiac
function and results in maladaptive changes that could lead to hypertrophy and
heart failure. Therefore, it is important to compare the difference between acute
vs. chronic PKA signaling on cardiac (patho)physiology regulation. Lastly, we will
examine the effects of Gq and -AR/PKA signaling using heart failure (HF) rabbit
myocytes to better understand the cellular mechanism of HDAC5 trafficking
between control and HF adult myocytes. Since -AR response is well known to
be downregulated during HF, any differential regulation of HDAC5 trafficking
between control and HF myocytes will represent an important physiological
epigenetic control by PKA via HDAC5 shuttling.
In summary, this aim will investigate the cross-interaction between Gq and
-AR signaling at the level of HDAC5 translocation between the nucleus and the
cytosol. In particular, we will contrast any differences between regulation of acute
vs. chronic PKA signaling on Gq-driven transcriptional control via HDAC5
shuttling.
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Aim 3: To determine the modulatory role of -AR/PKA activation on PKD
activation and its consequent effects on hypertrophic signaling
Neurohumoral signaling can activate PKD and CaMKII to mediate cardiac
hypertrophic responses. These two kinases have been previously reported to
have increased expression and activity in HF (Bossuyt et al., 2008). CaMKII and
PKD can both phosphorylate the transcriptional repressor, HDAC5, to mediate its
phosphorylation-dependent nuclear export (Backs et al., 2008; Bossuyt et al.,
2011; Harrison et al., 2010; Harrison et al., 2006; Wu et al., 2006). We have
recently uncovered that -AR/PKA activation alone can trigger nuclear
accumulation of HDAC5 and also blocks Gq-driven HDAC5 nuclear export if
followed by ET-1 or PE treatment (unpublished data). The data suggest that
acute -AR/PKA signaling is protective against hypertrophic response by Gqmediated transcriptional activation. One possible mechanism by which -AR/PKA
might inhibit HDAC5 nuclear export is by inhibiting upstream PKD activation to
block HDAC5 phosphorylation-dependent export.
My overall hypothesis is that -AR signaling or PKA activation
prevents HDAC5 nuclear export in part by limiting upstream PKD activation
by Gq-agonist, ET-1 and PE. The role of PKA in PKD activation in adult
cardiac myocytes is still unclear. There is evidence in immortal cell lines
demonstrating that PKA activation potentiates PKD activation via AKAP-Lbc
complex (Carnegie et al., 2004; Carnegie et al., 2008). Conversely, other reports
indicate a counter regulatory role of PKA on PKD activation, describing an
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inhibitory effect of PKA (Haworth et al., 2011; Haworth et al., 2007; Sucharov et
al., 2011). There is little information regarding this PKA-PKD crosstalk in adult
ventricular myocytes.
First, we will determine if -AR or PKA activation has any effect on PKD
activation in adult myocytes using GFP-tagged PKD1 adenoviral construct since
canonical PKD activation is characterized by its initial sarcolemmal translocation
followed by nuclear translocation (Bossuyt et al., 2011). In addition, we will also
probe for its S916 auto-phosphorylation using a S916 phospho-specific antibody
to measure PKD activation under -AR/PKA or Gq-agonist stimulation. We will
also use various DKAR constructs (general, membrane-targeted and nuclear) to
determine global and local PKD activity in response to -AR/PKA activation and
Gq-agonist stimulation. We will also compare any difference in PKD activation
between Gq-agonist alone with pre-activation of -AR/PKA.
Secondly, in silico analysis suggests that there exists a potential
consensus PKA phosphorylation site within the PKD sequence at serine 427
(S427), and this site was also recently reported to be a direct PKA
phosphorylation target using a peptide screeing array (Smith et al., 2011). To
further dissect the mechanism of PKA modulation on PKD activation, we will
create a mutant with an alanine substitution (S427A) or a glutamate substitution
(S427E) to test if PKA modulation on PKD activation is altered due to presence
of a non-phosphorylatable or phospho-mimetic mutation.
First, we will examine whether GFP-tagged PKD mutants, S427A or
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S427E, have altered translocation in response to ET-1 and PE with or without
ISO and forskolin pretreatment. The non-phosphorylatable mutant, S427A, would
abolish any PKA effects on PKD translocation if this residue was indeed the PKA
phosphorylation site. Conversely, S427E phosphomimetic mutant should
recapitulate PKA phosphorylation effect on PKD translocation in response to ET1 or PE in the absence of ISO or forskolin pretreatment.
Moreover, to study the cross-interaction of PKA-PKD signaling, I plan to
infect adenoviral constructs of GFP-tagged WT PKD, S427A and S427E variants
in adult cardiac myocytes and treat with ISO or forskolin. Using a GFP pull-down
method, I will compare the levels of PKA phosphorylation across all three
variants using two different PKA substrate phospho-antibodies. This assay will
reveal any difference in PKA phosphorylation of PKD in adult myocytes in
response to ISO or forskolin. If we observe any significant difference in PKA
substrate phosphorylation levels between the WT or mutant variants, the results
will suggest that S427 is the major PKA target site. Conversely, if we do not
detect any appreciable difference between the WT or the mutant, the data would
indicate that there could be alternative or additional PKA target sites on PKD. In
addition, PKA could also modulate PKD activity in an indirect manner via another
molecular partner, such as AKAP-Lbc, which has been reported to be a critical
scaffolding complex to play a role in multiple signaling pathways (Appert-Collin et
al., 2007; Carnegie et al., 2004; Carnegie et al., 2008; Diviani et al., 2011).
In conclusion, the results of this study will provide information on PKA
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modulation on spatiotemporal activation of PKD in adult cardiac myocytes. The
crosstalk between PKA-PKD signaling pathways can be critical in future
therapeutic design for hypertrophy and heart failure treatment where PKA
response is downregulated (Bristow et al., 1982; Choi and Rockman, 1999) and
PKD expression and activity are increased (Bossuyt et al., 2008).

CHAPTER 3
MATERIALS AND METHODS
The overall molecular cloning techniques and laboratory procedures are
described in this chapter. Critical experiments pertinent to the results of each
major chapter are included in individual chapters.

1.

Site-Directed Mutagenesis

We obtained the wildtype (WT) human PKD1 DNA plasmid from Dr. Eric
Rozengurt (University of California – Los Angeles). The adenovirus was kindly
generated by Dr. Jody Martin (Loyola University Chicago). General D kinase
activity report (DKAR) was purchased from Addgene (plasmid 14879). Our
collaborator, Dr. Alexandra Newton (University of California – San Diego),
generously provided us with the targeted DKAR plasmid for sarcolemmal and
nuclear DKAR. We inserted the DKAR into pShuttle-CMV vector to generate
adenovirus (figure 4 and 5).
We obtained both the GFP-tagged WT HDAC5 and HDAC5 SS259/498AA
adenovirus from Dr. Eric Olson (University of Texas – Southwestern). MEF2
luciferase reporter adenovirus was a gift from Dr. Jeff Molkentin (University of
Cincinnati – Children’s Hospital).
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We created the HDAC5 S279A and S279D mutants by site-directed
mutagenesis using Quik Change II XL Lightning kit (Agilent, catalog 200521).
The primers used for HDAC5 S279A and S279D are included in the table below.
We excised the plasmid from its pcDNA backbone and inserted into psh-CMV
using Hind III and Xba I (Figure 6).

HDAC5 primers
S279A-F

5'-ctgagcggagaagcgctcccctcctgcgtc-3'

S279A-R

5'-gacgcaggaggggagcgcttctccgctcag-3'

S279D-F

5'-ctgagcggagaagcgatcccctcctgcgtc-3'

S279D-R

5'-gacgcaggaggggatcgcttctccgctcag-3'

2.

Bacterial Transformation

For DNA amplification, the plasmid DNA was transformed into chemically
competent DH5 bacterial cells (Invitrogen). The bacterial cells were thawed on
ice. 5 l of plasmid DNA was added into 50 l of bacterial cells and incubated on
ice for 30 min. The mixture was heat shocked at 37 oC for 45 s immediately
followed by addition of 350 l of S.O.C medium (Invitrogen). The tubes were
placed on mechanical shaker at 225 rpm in 37 oC warm room for 1 hr. 100 l of
bacterial mixture was plated on agar plate with ampicillin (100 g/mL) or
kanamycin (50 g/mL) near an open flame and incubated at 37oC overnight.
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3.

Bacterial Plasmid Isolation

a) Small plasmid isolation (Promega PureYieldTM Plasmid Miniprep
System)
The small DNA plasmid was isolated according to the manufacturer’s
protocol. 1.5 mL of overnight culture was centrifuged for 1 min, and cell pellet
was re-suspended with 250 l of cell resuspension solution. 250 l of cell lysis
solution was added to each sample and inverted 4 times to mix. 10 l of alkaline
protease solution was added to each sample and inverted 4 times to mix. The
samples were incubated for 5 min at room temperature. 350 l of neutralization
solution was added and mixing by inverting 4 times. The mixture was centrifuged
at top speed for 10 min at room temperature. Vacuum adapters were attached to
manifold port and spin columns were inserted into adapter. Cleared lysates were
decanted into the column followed by applying vacuum to pull liquid through
column. 750 l of wash solution as added and this step was repeated with 250 l
of wash solution. The columns were dried by applying vacuum for 10 min. To
elute the DNA, the columns were transferred to a 1.5 mL eppendorf tubes. 50 l
of nuclease-free water was added to the column and centrifuged at top speed for
1 min at room temperature. The column was discarded and plasmid DNA was
stored at -20oC.
b) Large Plasmid Isolation (Promega PureYieldTM Plasmid Midiprep
System)
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The large plasmid isolation was prepared according to the manufacturer’s
protocol. 100 mL of overnight bacterial culture was pelleted at 5,000 x g for 10
min. The cell pellet was re-suspended with 3 mL of cell resuspension solution. 3
mL of cell lysis solution was added and tubes were inverted 3 times to mix. The
mixture was incubated for 3 min at room temperature. 5 mL of neutralization
solution was added and tubes were inverted 5 times to mix. The cell lysates were
centrifuged at 15,000 x g for 15 min at room temperature. A column stack was
assembled by placing a blue PureYieldTM clearing column on top of a white
PureYieldTM binding column and attached to a vacuum manifold. The cleared
lysate was poured into the clearing column followed by applying vacuum to pull
the liquid through both columns. The vacuum was released from the filtration
device and clearing column was removed, leaving the binding column behind. To
wash the DNA, 5 mL of endotoxin removal wash was added to the binding
column and vacuum was applied to pull the solution through. 20 mL of wash
solution was added to the binding column and allowed to pull through using the
vacuum. The vacuum was applied until the membrane was dried and binding
column was removed the vacuum manifold. To elute the DNA, 1.5 mL
microcentrifuge tube was inserted into the base of the EluatorTM vacuum elution
device (Promega, catalog A1071) and the device was assembled onto the
vacuum manifold with the binding column stack on top. 500 l of nuclease-free
water was added to the DNA binding membrane in the binding column followed
by applying vacuum for 1 min or until all the liquid was pulled through the column.
The microcentrifuge was removed from the device and DNA was stored at -20oC.
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4.

Adenoviral Generation

Phase I: Subcloning into pShuttle-Cytomegalovirus (psh-CMV)
DNA plasmid and pShuttle-CMV were digested with restriction enzymes
(New England Biolabs). The digested DNA fragment was inserted into the
multiple cloning site (MCS) of linearized pShuttle-CMV in a ligation reaction
incubated at 16oC overnight. The next day, the ligation product was transformed
into DH5 chemically competent cells. 100 l of bacterial mixture was plated on
agar plate with kanamycin (50 g/mL) and incubated at 37oC overnight. The next
day, colonies were picked to grow mini-cultures in 2 mL of Luria-Bertani (LB)
media with kanamycin (50 g/mL) at 37oC overnight. Small plasmid DNA was
isolated from the bacterial cultures using PureYieldTM Plasmid Miniprep System
(Promega) according to manufacturer’s instructions. The eluted DNA was
screened using Pac I enzyme (New England Biolabs) and cut at 37oC for 1.5 hr.
The digest was loaded with 6x loading dye (Promega) and run on a 0.8%
agarose gel at 130 V for 45 min. Positive samples should consist of two bands: a
3 kb band and a larger band (= 4.5 kb + insert size).

Phase II: Generation of Adenoviral DNA
Once subcloned into pShuttle-CMV, positive construct (2 g) was
linearized with Pme I (New England Biolabs) at 37oC for 1.5 hr. The DNA was run
on a 0.8% agarose gel to confirm linearity. The linear band was excised from
agarose gel and purified using Wizard SV Gel and PCR Clean up System
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(Promega). Once gel-purified, the DNA was transformed into BJ5183-AD-1
electroporation-competent cells (Invitrogen) using an electroporator (200 Ω, 2.5
kV, 25 μF) (Bio-Rad). The next day, the plate should yield in varying sizes of
colonies with large, medium and small colonies. Since recombination occurs at a
low rate, the tiny colonies were chosen to grow mini-cultures, and bacterial
plasmid DNA was isolated using Qiagen PREP SPIN miniprep kit (catalog
27106). The plasmid DNA was screened using Pac I and should yield in two
bands with a 3 kb band and a larger band (4.5 kb + insert). The recombinant
adenoviral DNA was transformed into chemically competent DH5 cells and
screened with Pac I.

5.

Adenoviral Plaque Generation and Amplification

The recombinant adenoviral DNA (10 g) was digested with Pac I at 37oC
for 2 h and cleaned using Wizard SV Gel and PCR Clean up System (Promega).
To begin generation of adenoviral plaques, 100 l of plain D-glucose Minimal
Esssential medium (DMEM) was added to the Pac I-digested adenoviral DNA
followed by adding 50 l of polyfect (Qiagen, catalog 301107). The mixture was
perturbed by tapping gently and incubated at room temperature in the culture
hood for 5-10 min. The total 200 l solution mixture was added drop by drop to
the 80% confluent human embryonic kidney (HEK) cells in 6 cm dishes. The
dishes were incubated at 37oC incubator. The next day, media was aspirated and
replaced with 3 mL of DMEM with 2% FBS and 5% penicillin/streptomycin. The
plaques with cytopathic effect (CPE) should become visible after 5 days in the
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monolayer of HEK cells using a phase-contrast microscope. The 6 cm HEK cells
should lyse completely after approximately 14 days. The dish was scraped and
transferred onto 10 cm dish to begin amplifying the adenoviral DNA. Once the 10
cm dish was completely lysed, the mixture was collected in 50 mL falcon tubes
and clarified by centrifugation at 2,000 rpm for 5 min. The supernatant was
added to thirty 10 cm dishes of 80% confluent HEK cells in DMEM with 2% fetal
bovine serum (FBS) and 5% penicillin/streptomycin. The HEK cells were
harvested after 2-3 days and pelleted at 2,000 rpm for 5 min. The virus pellet was
collected into one tube using 4 mL of 1x phosphate buffered saline (PBS) and
flash-frozen in liquid nitrogen. The excess adenoviral solution (50 mL) was kept
at -20oC for future amplification.

6.

Adenoviral DNA Purification

The adenovirus pellet was extracted using 3 freeze/thaw cycles and
resuspended using a vortex mixer. The mixture was pellet at 4,000 rpm for 5 min,
and 1 mL of supernatant was aliquoted into eppendorf tubes. The supernatant
was clarified further by centrifuging at 14,000 rpm for 10 min at 4 oC to separate
the cell debris from the adenoviral particles. The adenoviral DNA was purified
using a cesium chloride (CsCl) gradient method. To begin gradient purification in
Beckman centrifuge tube, 1.2 g/mL CsCl was added first to the bottom, followed
by addition of 1.45 g/mL CsCl to the bottom of the tube without disturbing the top
layer. The volume ratio of 1.2 g/mL to 1.45 g/mL should be a little less than 2:1.
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Once complete, there should be a grey ring formed between the two
density layers of CsCl. The adenoviral supernatant was added to the top of CsCl
gradient leaving 0.5 inches on the top. The Beckman centrifuge tubes were
balanced before inserting into Beckman ultra centrifuge tubes and centrifuged at
22,000 rpm for 2.5 hr at 4oC. The mature adenovirus was collected by extracting
the particles using a 22G needle and injected into Slide-A-Lyzer Dialysis
Cassette (with molecular weight (M.W.) cutoff at 10,000 kDa). The cassette was
placed in 1x PBS dialysis buffer at 4oC overnight followed by replacement of
fresh 1xPBS for additional 2 hr the next day to remove the CsCl. The adenovirus
was extracted from the cassette using a 22G needle once dialysis was complete
and kept at -80oC with 10% glycerol.

7.

Rat Cardiomyocyte Isolation

We isolated ventricular myocytes from rat (Sprague Dawley purchased
from Charles River Laboratories) as described previously (Bassani et al., 1994).
All animal procedures performed were in accordance to Institutional Animal Care
and Use Committee regulations at University of California – Davis. The rat cell
isolation was performed by our technicians, Khanha Dao and Matthew Stein. The
rat was injected with 0.3 mL (1,000 units) heparin subcutaneously 30 min prior to
1.4 mL Nembutal (50 mg/mL). The enzyme and 0 Ca2+ minimal essential medium
(MEM) solutions were pre-warmed in 37oC water bath. 5 mL of the enzyme with
MEM solution was set aside in a beaker in the shaker bath. 15 mL of 0 Ca 2+
MEM solution and 0.2 mL heparin in each of three 20 mL beakers and 5 mL of 0

Ca

2+
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MEM solution in a syringe on ice. A connector attached to the cannula was

affixed to the perfusion set-up. The suture was loosely fit around the cannula in
preparation of tying the aorta. The perfusion apparatus was primed with 0 Ca2+
MEM solution to eliminate air bubbles. Before beginning surgery, rat’s eyes and
footpad reflexes were checked and tested. The chest area was soaked with
ethanol followed by pinching and cutting away the skin. The ribs were opened
with reinforced titanium scissors to create a flap. The heart was removed by
cutting the aorta and washed by sequentially transferring it through 0 Ca 2+ MEM
solution beakers on ice (3x). The heart was quickly cannulated and perfused with
0 Ca2+ MEM solution for 3-5 min. The heart was perfused with enzyme solution.
After first minute of enzyme perfusion, the enzyme solution was collected and
recycled. Total enzyme perfusion is about 12 min. The heart (ventricles only) was
cut to be released from the cannula leaving the atria behind. The ventricles were
placed in a petri dish with 15 mL of enzyme solution and triturated carefully. 20
mL of bovine serum albumin (BSA) solution was added and cell pellets were resuspended for 1 min using a wide-bore Pasteur pipette. The cell mixture was
filtered through 210 m mesh in three 15 mL falcon tubes. The solution was
centrifuged for 1 min and supernatant was removed. The remaining pellet was
re-suspended in a mix of BSA solution with final wash solution (1:1 ratio) and
filed through 210 m mesh in two 15 mL falcon tubes (if necessary). The filtrate
was allowed to rest for 10 min. The supernatant was removed and re-suspended
in 7 mL of final wash solution. The cells were gravity settled for 5 min (2x). The
supernatant was removed the re-suspended in 8 mL of final wash solution before
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plating.

8.

Rabbit Myocyte Isolation

We isolated ventricular myocytes from adult New Zealand white rabbit
(purchased from Charles River Laboratories) as described previously (Bassani et
al., 1994). All animal procedures used were in accordance to Institutional Animal
Care and Use Committee regulations at Loyola University Chicago and
University of California – Davis. The cell isolation procedure was performed by
technicians Charles Wilkerson, Khanha Dao and Matthew Stein. The Langendorf
perfusion system was rinsed with Baxter purified water (3x) and 37 oC water bath
was turned on. Adult New Zealand white rabbit was retrieved and gently placed
in restrainer. The rabbit was heparinized with 0.16 c.c of heparin (50,000
units/mL) subcutaneously for 30 min. During this period, the following items were
prepared as follows: 40 mL of initial wash solution was poured into three 100 mL
beakers, and two 60 mL syringes were also filled with initial wash solution and
chilled on ice for 30 min prior to surgery. The remaining initial wash solution was
poured into the Langendorf system, and oxygen was turned on. After 30 min of
heparin incubation, 3.6-4.2 mL of Nembutal/sodium pentobarbital was obtained in
a 5 mL syringe and attached to a 27G butterfly needle. The drug was injected
intravenously into the rabbit ear. The rabbit was checked for vital response (by
pinching toe on the footpad) and placed with a gas mask of 100% O 2 to maintain
oxygenation of the blood if it was unconscious. The chest area of the rabbit was
sprayed with 70% ethanol immediately followed by opening of the chest with
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scissors. Once the chest was opened, the diaphragm was cut to remove the
beating heart from the pericardial sac. The heart was quickly rinsed in beakers
containing chilled initial wash solution. The heart was promptly cannulated and
secured tightly. The cannulated heart was flushed using 60 mL syringes with
chilled initial wash solution. Prior to clamping, pooled blood within the heart was
removed using a transfer pipette. Any opening vessels were clamped close while
allowing initial wash to run through. Collagenase enzyme was added and allowed
to digest the heart tissue for approximately 28 min. During the enzyme digestion,
the heart should remain pink, soft but firm. It was observed for any changes in
texture. Once the digestion was complete, the heart was taken down, cut into
pieces and carefully triturated. The BSA solution was poured into the diced heart
mixtures. Any loose cells were removed and more BSA was added. The cells
were incubated in warm water bath for 2 more min. This was repeated one more
time. The remaining BSA was used to triturate the residual tissue to extract extra
cells. The myocytes were spun down using a hand centrifuge for 5 min. The
supernatant was filtered to remove excess fat tissue. The cell pellet was
resuspended in 20 mL of final wash solution and extra BSA. The cells were
allowed to gravity settle for 10 min, and the supernatant was removed. The pellet
was resuspended further in 20 mL of final wash and gravity settled for 5 min. The
supernatant was removed and remaining cell pellet was resuspended in final
wash before plating on petri-dishes.
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9.

Heart Failure Animal Model

Heart failure was induced in adult New Zealand White rabbit as described
previously (Pogwizd S et al. 1999). Briefly, HF was induced by two sequential
survival surgeries by first inducing aortic insufficiency and after 2-8 weeks postop monitoring, followed with aortic constriction. Each rabbit was monitored with
echocardiogram to determine the severity of the HF status (typically 4-6 months)
and scheduled for isolation procedure accordingly.

10.

Cell Culturing

Acutely isolated adult ventricular myocytes were collected in a falcon tube
and allowed gravity settled. The supernatant was aspirated and replaced with
warm PC-1 medium (Lonza) with 5% penicillin/streptomycin and supplement. 2well Borosilicate coverglass chambers (Fisher Scientific, catalog 155380) were
coated with laminin mixture and allowed to air-dry. Myocytes were re-suspended
using fresh PC-1 medium, and 1.5 mL of cell resuspension was added into each
well. The myocytes were incubated at 37oC incubator for attachment for 45 min.
The cells were gently washed and incubated with fresh PC-1 medium before
addition of adenovirus (multiplicity of infection, MOI = 10-100) and incubated at
37oC overnight.

11.

Confocal Imaging

2-well Borosilicate coverglass chamber was mounted on an inverted
microscope (Zeiss, LSM5 Pascal or Olympus) equipped with 40x water
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immersion object lens. Argon laser (3-5%) was used to excite GFP at 488 nm,
and emission wavelength was collected with long-pass filter above 505 nm. A
schematic of confocal LSM 5 is illustrated in figure 7. PC-1 medium was replaced
with normal tyrode solution (10 mM glucose, 140 mM sodium chloride (NaCl), 1
mM magnesium chloride (MgCl2), 4 mM potassium chloride (KCl), 5 mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)) containing 1.8 mM Ca2+
before each experiment. Cells were imaged before and after treatment with
agonists.
National Institute of Health (NIH) Image J software was downloaded from
its website: http://rsbweb.nih.gov/ij/download.html and was used for image
analysis. A similar analysis method was used for measuring sarcolemmal and
nuclear translocation of PKD1-GFP and nucleaocytoplasmic shuttling of HDAC5.
For example, the nucleus was traced with region of interest (ROI) to measure its
fluorescence intensity and divided by the average of three randomly selected
ROIs of equal size in the cytoplasm to compare the nuclear vs. cytosolic signal.
Each Fnuc/Fcyto ratio was normalized to initial time point (time 0) for comparison
before and after drug treatment and between different data groups.

12.

Immunoblotting

The samples were loaded onto 4-20% gradient SDS-PAGE gels (Biorad)
and subject to electrophoresis at 90V for 2 h. Upon completion, the gels were
transferred onto nitrocellulose membranes in 1 L of transfer buffer (125 mL of
electroblot stock, 20% methanol and 675 mL of cold water) at 20 V in 4oC cold

56
room overnight. Once transfer was complete, the nitrocellulose membrane was
rinsed with water (2x) followed by 1x tris buffered saline (TBS) (2x) for 5 min. The
membrane was incubated with blocking solution (0.2% Tween, 8% milk, 1x TBS)
for 1 hr and rinsed with 1x TBST (tris buffered saline tween) (3x). The membrane
was cut and incubated with primary antibody in 1x TBST at optimal concentration
at 4oC overnight. The antibody used for each experiment was included in each
chapter. The primary antibody was washed off using 1x TBS (5 min), 1x TBST (2
x 10 min), 1x TBS (5 min) and 1x TBST (10 min). The membrane was then
incubated with appropriate secondary antibody (goat anti-rabbit ImmunoglobulinG (IgG) or anti-mouse IgG conjugated with horseradish peroxidase (HRP)) at
1:5000 dilution with 0.2% milk in 1x TBST at room temperature for 1 hr. The
secondary antibody was washed off using 1x TBS (5 min), 1x TBST (2 x 10 min),
1x TBS (5 min) and 1x TBST (10 min). The membrane was developed using
West Dura (Pierce, catalog 34076) for 5 min and imaged with ImageReader LAS
4000. Densitometry analysis was performed using Image J software (NIH).

13.

Statistical Analysis

Pooled data are represented as mean + standard error of measure (SEM).
Statistical significance was determined using either Student’s t-test (unpaired) or
one way analysis of variance (ANOVA) followed by Bonferroni’s post-hoc test. * p
< 0.05 was considered statistically significant.
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DKAR & Targeted- DKAR in pcDNA3.1 (+)
DKAR
~1.8 Kb

Figure 4. Map of DKAR in pcDNA. Construct map of DKAR in pcDNA vector.
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DKAR & Targeted- DKAR into pshCMV (DAM-)
Hind III
DKAR
~1.8 Kb
Xba I

XbaI

Figure 5. Map DKAR in psh-CMV vector. We inserted DKAR into psh-CMV
using Hind III and Xba I restriction enzymes.
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HDAC5-S279A/D into psh-CMV (Dam-)

Hind III Xba I

Figure 6. Map of HDAC5-S279A/D in psh-CMV. We used Hind III and Xba I to
insert HDAC5-S279A and HDAC5-S279D mutant into psh-CMV vector.
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Figure 7. Schematic of beam path in the confocal LSM 5 PASCAL Laser
Scanning Microscope. Image taken from Zeiss LSM 5 PASCAL manual.

CHAPTER 4
AIM 1

“Spatiotemporally Distinc Protein Kinase D Activation in Adult Cardiomyocytes in
Response to Phenylephrine and Endothelin”

Introduction
Cardiac hypertrophy and remodeling can be induced by diverse stress
stimuli ranging from mechanical stress, pressure overload, oxidative stress to
neurohumoral signaling (Frey and Olson, 2003; McKinsey, 2007). The
remodeling process exhibits initial beneficial functional effects, but eventually
triggers maladaptive changes that deteriorate the heart to pump blood effectively.
The remodeling process becomes pathological and typically progresses towards
heart failure. To induce cardiac hypertrophic growth, the process needs to be
initiated by epigenetic re-programming to encourage protein synthesis (Avkiran et
al., 2008). The transcriptional activation during such genetic re-programming has
been linked to a family of transcriptional repressors, called class II HDACs
(Backs et al., 2008; Bertos et al., 2001; Yang and Gregoire, 2005; Zhang et al.,
2002).
In particular, HDAC5 has been reported to regulate cardiac hypertrophy
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via its association with transcription factor, myocyte enhancer factor 2 (MEF2)
family (Chang et al., 2004; Lu et al., 2000a; Lu et al., 2000b; McKinsey et al.,
2000a). The functional role of HDAC5 serves to repress target gene expression
through condensation of chromatin structure by removal of acetyl groups from
histone tails (Backs and Olson, 2006; McKinsey and Olson, 2005). Both CaMKII
and PKD have been reported to phosphorylate HDAC5 to mediate its nuclear
export (Backs et al., 2008; Ellis et al., 2003; Harrison et al., 2010; Harrison et al.,
2006; Wu et al., 2006), and emerged as crucial transducers of extracellular
stress stimuli to HDAC5 signaling. Moreover, CaMKII and PKD are found to have
increased expression and activity in failing myocardium supporting their potential
as therapeutic targets in the future (Bossuyt et al., 2008; Harrison et al., 2006).
Although PKD was initially discovered as a member of the PKC family, it
was later re-categorized into the CaMK superfamily based on its enzymatic
function and substrate specificity (Avkiran et al., 2008; McKinsey, 2007). PKD is
a serine/threonine kinase that is involved in diverse cellular processes, such as
signal

transduction,

cellular

proliferation,

ischemia/reperfusion,

immune

regulation, cardiac hypertrophy, contraction and cancer (Bardswell et al., 2010;
Fu and Rubin, 2011; Ghanekar and Lowe, 2005; Liu et al., 2007; Matthews et al.,
2006; Xiang et al., 2011). PKD family contains three isoforms of PKD (PKD 1, 2
and 3), which share relatively conserved sequence homology and domain
function (Avkiran et al., 2008; Wang, 2006)
While PKD1 is the predominant cardiac isoform, it has also emerged as a
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key protein in cardiovascular research since PKD has been involved in regulating
cardiac pathophysiology in multiple ways. For example, it plays a role in
phosphorylating HDAC5 to mediate its nuclear export during hypertrophic
signaling (Bossuyt et al., 2008; Harrison et al., 2010; Harrison et al., 2006; Vega
et al., 2004), and cardiac troponin I to modulate myocyte contraction via altering
its Ca2+ sensitivity (Bardswell et al., 2010; Cuello et al., 2007; Goodall et al.,
2010; Haworth et al., 2004). Transgenic mice with overexpression of
constitutively active PKD1 showed enlarged heart (Harrison et al., 2006).
Similarly, cardiac-specific deletion of PKD1 effectively reduced cardiac
hypertrophy induced by aortic constriction (Fielitz et al., 2008). Thus, all these
data strongly support the regulatory role of PKD1 in cardiac hypertrophic
signaling and demands further understanding of its fundamental activation
mechanism in adult myocytes.
PKD consists of two cysteine-rich regulatory domains (C1a and C1b) near
the N-terminus, a pleckstrin-homology domain in the middle and a C-terminal
catalytic domain (Hayashi et al., 1999; Sturany et al., 2001; Valverde et al.,
1994). The C1 domains of PKD share similar function to those in PKC, to
mediate reversible plasma membrane translocation in response to DAG
produced by GPCR activation or phorbol esters (Newton and Johnson, 1998). To
date, the canonical mechanism of PKD activation depicts initial upstream PKC
phosphorylation at S744/S748 within the catalytic domain, followed by PKD
autophosphorylation at S916 residue (Matthews et al., 1999; Rey et al., 2004;
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Rozengurt et al., 2005; Waldron and Rozengurt, 2003; Wang, 2006). A possible
Ca2+-dependent mechanism of PKD activation is also recently reported (Kunkel
et al., 2007; Wu et al., 2006). While PKD was found to be the major HDAC5
kinase in cultured neonatal rat myocytes (Vega et al., 2004), however, its
expression in adult myocyte is known to be significantly reduced compared to
neonates (Haworth et al., 2000). This raises the question of PKD role in
regulating HDAC5 translocation in adult myocytes.
We have previously identified an IP3-CaMKII pathway for the ET-1 induced
HDAC5 nuclear export in adult myocyte (Wu et al., 2006). In this study, we
examine and contrast the spatiotemporal PKD activation in response to two
common neurohumoral stimuli, ET-1 and PE in adult myocytes. PE is an adrenergic agonist, which also has been reported to induce cardiac remodeling
(Vega et al., 2004). Our current data show subcellular local activation of PKD is
differentially regulated by ET-1 and PE although these two Gq-agonists induce
comparable global PKD activation and HDAC5 nuclear export. PE-mediated PKD
activation is found to be independent of IP 3-CaMKII signaling in contrast to the
PKD activation induced by ET-1. Moreover, PE induces rapid, transient PKD
translocation to the sarcolemma followed by quick nuclear import of active PKD
to phosphorylate HDAC5 in the nucleus. Conversely, ET-1 exhibits PKD
translocation that stays bound to the sarcolemma longer and results in slower
and smaller nuclear PKD activation. This is consistent with our previous study
where IP3-CaMKII signaling is the major pathway involved in ET-1 mediated
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HDAC5 nuclear export (Wu et al., 2006). Our current study provides a critical
evaluation of dynamic spatiotemporal PKD activation in both global and local
environments. This study indicates that Gq-agonists, ET-1 and PE, diverge in
their signaling to preferentially activate CaMKII and PKD respectively to regulate
HDAC5 translocation in adult myocytes.
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Materials and Methods
Myocyte isolation and adenoviral infection
All animal and biohazard protocols were approved by the appropriate
committees at the University of California, Davis. Rabbit ventricular myocytes
were isolated as previously described (Bassani et al., 1994) and plated on
laminin-coated culture inserts. Culture media was PC-1 media (Lonza)
supplemented with 5% penicillin-streptomycin. Myocytes were infected for 2 hr
(MOI = 10-50) with recombinant replication-deficient adenovirus expressing
HDAC5-GFP, PKD1-GFP or DKAR variants, with subsequent culture for 20-30
hr. GFP fluorescence (CFP/YFP for DKARs) indicated infection and localization.
For non-targeted DKAR experiments, ventricular myocytes were also infected
with adenovirus encoding PKD1. To ensure adequate infection of myocytes (lack
of GFP expression) protein expression of PKD was assessed by Western
blotting. After 24 hr, myocytes were exposed for 1 hr to 100 nM ET-1, 10 µM PE,
200 nM PDBu or vehicle as indicated. These experiments were performed with or
without 1 µM KN-93, 10 µM BisI, 2 µM 2-APB or 10 µM Gö6967 pretreatment for
20 min.

Immunoblotting and Immunocytochemistry
Isolated myocytes were rinsed in PBS and treated as indicated before
lysing in ice-cold buffer containing in mM: 150 NaCl, 10 Tris (pH 7.4), 2 EGTA,
50 NaF, 0.2 NaVO3, 1% Triton X-100, and protease and phosphatase inhibitor
cocktail III (Calbiochem). Cell lysates were flash-frozen and stored at -80°C.
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Proteins were size-fractionated on 8% SDS-PAGE before transferring to a 0.2
micron nitrocellulose membrane. Immunoblots were blocked with 8% milk in
TBST. The blots were then incubated overnight at 4°C with primary antibody:
PKD, PKD-pS916 or PKD-pSS744/748 (1:1000; Cell Signaling). After incubation
with the HRP–labeled secondary antibody, blots were developed using enhanced
chemiluminescence (Pierce Supersignal). All signals were recorded using a
UVP-EpichemII darkroom imaging system for quantification and captured on film
for representation. Equal protein loading was ensured by reprobing for
glyceraldehype 3-phosphate dehydrogenase (GAPDH) (1:5000; Abcam). All
experiments were performed in duplicate. For immunostaining myocytes seeded
on glass coverslips were fixed with 4% para-formaldehyde in PBS. After
incubation in PBS with 0.1% glycine, cells were permeabilized with 1% Triton X100 and incubated with anti-PKD (1:50, overnight, 4°C). This was visualized with
anti-rabbit (Alexa488).

Confocal measurements
GFP-HDAC5 and PKD1-GFP signals were measured by confocal
microscopy with argon laser excitation at 488 nm and emitted fluorescence (F) at
LP 500. Image J software (http://rsb.info.nih.gov/ij/) was used for analysis with
the intensity of the regions of interest normalized to area. Fluorescence
intensities were also corrected for background signal. For quantification of
recruitment to Z-lines, a plot profile was fitted to a sinusoidal equation and the
amplitude was taken as the Z-line signal.
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Fluorescence resonance energy transfer (FRET) measurements
FRET was measured 2 ways. (1) a non-destructive, ratiometric technique
was used to monitor time-dependent FRET changes (and this also helped to
verify that the DKAR signal was not saturated under the conditions used). In this
method CFP and YFP emission are measured upon CFP excitation (N.B. relative
abundance of donor and acceptor is not an issue for DKAR) (Van Munster et al.,
2005). The following protocol was used: 100 ms acquisitions of CFP image (CFP
excitation and emission), 100 ms acquisitions of YFP image (YFP excitation and
emission), and finally 100 ms acquisition of FRET image (CFP excitation but YFP
emission). This is then followed by the second approach, the acceptor
photobleach method, where FRET efficiency was measured quantitatively as the
increase in donor (CFP) fluorescence upon YFP photobleaching (which
eliminates energy transfer from the donor to YFP) (Van Munster et al., 2005).
Here, YFP was progressively photobleached using 100 ms acquisitions of CFP
image, 40 ms acquisitions of YFP image, followed by repeated 10 s exposure to
YFP-selective photobleach (504/12nm excitation). This protocol has been
validated with FRET-standard samples (Kelly et al., 2008).
Fluorescence imaging utilized an inverted microscope equipped with a
1.49NA objective, and a back-thinned CCD camera (iXon 887, Andor
Technology). Image acquisition and acceptor photobleaching was automated
with custom software macros in MetaMorph that controlled motorized
excitation/emission filter wheels (Sutter Instrument Co.) with filters for CFP (Ex
427/10, Em 472/30 nm) and YFP (Ex 504/12 nm, Em 542/27) (Semrock).
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Statistical analysis
Data are expressed as mean + SEM. Statistical discriminations were performed
with Student’s t test (paired when appropriate), and ANOVA with p<0.05 was
considered significant.
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Results
Role of PKD in the regulation of HDAC
ET-1-induced HDAC5-GFP nuclear export and excitation-transcription
coupling in adult cardiac myocytes is entirely dependent on local InsP 3-induced
Ca2+ release and CaM, and depends equally on CaMKII and PKD
phosphorylation of HDAC5 (Figure 8) (Wu et al., 2006). Figure 9 shows that in
adult rabbit ventricular myocytes PE (another Gq-coupled receptor hypertrophic
agonist) produces very similar HDAC5-GFP nuclear export to ET-1 (34±2% vs.
35±2% at 60 min). Control studies confirmed that the ET-1 and PE
concentrations used are maximally activating. However, PKC inhibition (with Bis
I) virtually abolished PE-induced HDAC5 nuclear export, without altering that
induced by ET-1 (Figure 10). Also PKD blockade (with Gö6976, a PKC/PKD
inhibitor) caused ~50% inhibition of ET-1-induced HDAC5 translocation, and
again completely blocked PE-induced effect. Conversely, pretreatment with the
CaMKII inhibitor KN93 or the InsP3R blocker 2-APB did not significantly alter the
PE response, but potently inhibited the ET-1-induced HDAC5 nuclear export
(Figure 11). Parallel effects were observed for PE- vs. ET-1-induced MEF2
transcriptional activation, using a MEF2-luciferase reporter construct in adult
rabbit ventricular myocytes (not shown). These experiments indicate that PKCdependent PKD activation is required for PE-induced HDAC5 nuclear export
(independent of InsP3-dependent Ca2+ release or CaMKII). This contrasts with
the ET-1-dependent pathway, which requires InsP3-sensitive Ca2+ stores and
both CaMKII plus PKD, but not PKC. Thus, each Gq-coupled receptor agonist
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(ET-1 and PE) activates divergent signaling pathways in adult cardiac
myocytes. This also indicates that ET-1-induced PKD activation might be PKC
independent while that by PE requires PKC.

Notably, inhibition of PLC by

U73122 blocks PKD activation by both ET-1 and PE, consistent with DAGdependent activation of PKD that is independent of PKC, as suggested by
previous work (Harrison et al., 2006; Haworth et al., 2000).
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Figure 8. Agonist-dependent differential signaling of HDAC5. Schematic
diagram of ET-1 and PE signaling to HDAC5 in adult cardiac myocytes. ET-1
signaling triggers activation of CaMKII to mediate HDAC5 nuclear export while
PE differentially activates PKD to induce HDAC5 nuclear export.
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Figure 9. ET-1 and PE mediate nuclear export of HDAC5. Top: Confocal
imaging of WT HDAC5-GFP expression in adult cardiac myocyte. Example of
PE-induced nuclear export of HDAC5-GFP vs. control is shown. Bottom: ET-1
(100 nM) and PE (20 M) trigger comparable nuclear export of HDAC5 at 1 hr
post-treatment.
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Figure 10. ET-1 and PE exhibit different PKC and PKD signaling
dependence on mediating HDAC5 nuclear export. Cultured adult myocytes
were incubated with Bis I (10 M) or Gö 6976 (10 M) for 20 min before ET-1
(100 nM) or PE (20 M) treatment.
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Figure 11. ET-1 and PE signaling demonstrate differential activation of IP3CaMKII in triggering HDAC5 nuclear export. Cultured adult myocytes were
pretreated with CaMKII inhibitor, KN93 (1 M), or IP3 receptor blocker, 2-APB (2
M), for 20 min prior to ET-1 (100 nM) or PE (20 M) stimulation.
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PE and ET-1 differ in their ability to activate PKD1
Figure 12 shows that exposure to PE, ET-1 or the phorbol ester phorbol
12,13-dibutyrate

(PdBu)

cause

a

similar

5-fold

increase

in

PKD

autophosphorylation levels at S916 (often used as a read-out of PKD1 activity).
PE and PdBu both strongly activated phosphorylation of the activation loop
SS744/748 sites on PKD1 (by ~4-fold), but ET-1 was much less effective in
causing phosphorylation at SS744/748. Since PKC is known to phosphorylate
these sites (Rey et al., 2004; Rozengurt et al., 2005), this is consistent with the
more pronounced PKC dependence for PE-induced HDAC5 nuclear export (vs.
ET-1; Figure 10).
To more directly measure PKD activity and activation time course in adult
cardiac myocytes, we used the FRET-based PKD activation reporter (DKAR)
(Kunkel et al., 2007). DKAR includes a PKD-specific substrate and phosphoamino acid binding domain linking CFP and YFP, such that upon phosporylation
by PKD, FRET is reduced (Figure 13). Monitoring the CFP/YFP ratio, we found
that PE and ET-1 activated global PKD activity to a similar degree in adult
myocytes (Figure 14). We also used an additional DKAR FRET measurement,
i.e. donor fluorescence enhancement upon acceptor photobleach (figure15). This
quantitative method also showed similar PKD activity after 20 min exposure to
PE, ET-1 and PDBu. These results are consistent with our in vitro surrogate
measure of PKD activity (phospho-S916 PKD) in Figure12. These changes in
DKAR FRET were reversible upon agonist withdrawal and blocked by
pretreatment with Gö6976 (not shown).
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The similar PKD activation by PE and ET-1 (Figure 12 to Figure 15) does
not explain how these two Gq-coupled receptors differently affect HDAC5 nuclear
export and transcriptional activation (i.e. why is PKD much more critical for PE
vs. ET-1 signaling to the nucleus?). It is possible that PKD localization and
translocation differ for PE and ET-1, as PKD can redistribute among intracellular
targets in other cell types (Matthews et al., 2000; Rey et al., 2001). We explored
this using PKD1-GFP fusion proteins expressed in adult rabbit ventricular
myocytes using an adenoviral vector.
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active PKD phosphorylating its pseudo-substrate resulting in conformational shift
between CFP and YFP. Bottom: Expression of DKAR sensor in adult myocyte is
shown with selective excitation of CFP, YFP or FRET (excitation of CFP,
detection of YFP emission).
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Figure 14. Agonist-dependent real-time ratiometric DKAR measurements.
Cultured adult myocytes (expressing both DKAR and PKD1) were treated with
ET-1 (100 nM), PE (20 M) or PdBu (200 nM) for 20 min. n = 6.
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Figure 15. Acceptor photobleach-induced enchancement of CFP in
response to agonist. Cultured adult myocytes were treated with agonist, ET-1
(100 nM), PE (20 M) or PdBu (200 nM) for 20 min followed by photobleaching
the acceptor YFP to measure increase in CFP (correlates with PKD activity).
Data were represented as % change in FRET signal. n = 6.
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Spatiotemporal dynamics of PKD1 localization in response to PE and ET-1
Confocal imaging of adenovirally expressed PKD1-GFP fusion protein and
of immunostained endogenous PKD1 revealed that at rest, PKD1 expression is
relatively uniform and cytosolic (slightly higher at Z-line/transverse tubule region),
and largely non-nuclear (Figure 16) (Fnuc/Fcyto is 0.5±0.03 and 0.68±0.06,
respectively). Application of ET-1 caused rapid, sustained PKD recruitment to the
plasma membrane or sarcolemma (SL) (SL, 39±4% increase), with only a
modest and much delayed nuclear import (9±3%; or 23% of the SL increase). In
striking contrast, PE only slightly increased membrane PKD (7±2%), but much
more strongly increased nuclear translocation (25±2%; or 357% of the SL
increase) (Figure 16 and Figure 18). Note also that the smaller rise in nuclear
PKD1 concentration with ET-1 happens with a clear delay and as the SL starts to
decline. These findings indicate that ET-1 drives SL recruitment of PKD1, while
PE drives rapid nuclear recruitment of PKD1 (consistent with a more prominent
role in nuclear HDAC5 phosphorylation).

Similar results were obtained with

immunostaining of endogenous PKD1 in adult rat myocytes (data obtained by
Linda Lee) (Figure 17), validating the use of PKD1-GFP as a tracer for the
endogenous protein (not all data shown). PKD1 is also recruited to the T-tubular
membrane (SL invaginations in cardiac myocytes), as indicated by the
sharpening of the fluorescence intensity at the Z-line/T-tubule location vs. the
mid-sarcomere region (Figure 19). Moreover, the relative strength of agonists
(PdBu> ET-1> PE) causing T-tubule concentration was the same as that for
surface SL (Figure 18).
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Figure 16. Agonist-induced GFP-PKD1 translocation. Examples of confocal
imaging showing cultured adult myocytes treated with ET-1 (100 nM), PE (20
M) or PdBu (200 nM).
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Figure 17. Endogenous PKD1 localization in isolated adult myocytes. Top:
Immunostaining of endogenous PKD1 localization using PKD1 specific antibody.
Middle: Example of endogenous ET-1 induced PKD1 translocation to the
sarcolemma. Bottom: Immunostaining of PKD1 co-localization with -actinin.
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Figure 18. Sarcolemmal and nuclear translocation of PKD1 in adult
myocytes.
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translocation in response to ET-1 (100 nM), PE (20 M) or PdBu (200 nM). Right:
Nuclear translocation of GFP-PKD1 after treatment with ET-1 (100 nM), PE (20
M) or PdBu (200 nM).
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Figure 19. PKD1 translocation in T-tubules. Left: Example of confocal signal of
GFP-PKD1 translocation to the T-tubular membrane after PdBu treatment (200
nM). Right: Confocal measurements of GFP-PKD1 translocation to the T-tubules
in response to ET-1 (100 nM), PE (20 M) or PdBu (200 nM).
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Spatiotemporal dynamics of PKD1 activity in response to PE and ET-1
We also used targeted PKD activity reporters to measure its localized
activation at the sarcolemma (DKAR-SL) and the nucleus (DKAR-Nuc)
respectively. All three agonists elicited a similar increase in PKD activity at the
SL (FRET was reduced 31±5%, 31±4% and 24±5% for PDBu, ET-1 and PE
respectively; based on acceptor bleach induced donor enhancement) (Figure
20). In contrast PE was much more potent in activating nuclear PKD than either
ET-1 or PDBu (Figure 21). This was also apparent in the real-time, ratiometric
FRET measurements of nuclear and sarcolemmal PKD activity. PE and ET-1
triggered similar responses at the sarcolemma, whereas ET-1 caused a small,
slow rise in nuclear PKD activity while PE elicited a faster and larger response
(Figure 22). These findings are consistent with a more pronounced nuclear role
for PKD1 upon PE than ET-1 stimulation.
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Figure 20. Agonist-dependent activation of sarcolemmal PKD activity. Left:
Membrane-targeted DKAR measurement of PKD activity after treatment with
PdBu (200 n<), ET-1 (100 nM) or PE (20 M). Right: Representative DKAR-SL
expression in adult myocyte with pronounced membrane appearance. *p<0.05
vs. control.
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Figure 21. Agonist-dependent nuclear PKD activity. Left: Nuclear-targeted
DKAR measurement of PKD activity after treatment with PDBu (200 nM), ET-1
(100 nM) or PE (20 M). Right: Representative DKAR-Nuc expression in adult
myocyte with pronounced nuclear localization. *p<0.05 vs. control.
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Figure 22. Differential PKD activation by ET-1 and PE at the nucleus and the
sarcolemma. Left: DKAR-Nuc measurements reflected that PE induced a
stronger PKD nuclear activation vs. ET-1. Right: DKAR-SL showed comparable
membrane activation of PKD by ET-1 and PE.
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nuclear translocation.
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Discussion
PKD and CaMKII are crucial mediators of cardiac hypertrophic signaling
and remodeling, thus are desirable pharmacological drug candidates for cardiac
therapy (Harikumar et al., 2010; McKinsey and Olson, 2005; Meredith et al.,
2010a; Meredith et al., 2010b; Monovich et al., 2009; Monovich et al., 2010).
Although both kinases can be activated by common neurohumoral stimuli, ET-1
and PE, the differential signaling mechanism between the two pathways remain
to be elucidated in adult cardiac myocytes. In this study, we demonstrate for the
first time that ET-1 and PE have distinct signaling pathways that allow divergent
activation of CaMKII and PKD to phosphorylate their mutual downstream target,
HDAC5. Our findings suggest that there is redundant hypertrophic signaling by
these two Gq-agonists to provide differential epigenetic modulations via HDAC5
translocation in adult cardiac myocytes.
Extensive work by Olson’s group in cell lines and neonatal myocytes
indicates that HDAC4 nuclear export is facilitated by CaMKII phosphorylation
while HDAC5 is phosphorylated by PKD (Backs et al., 2008; Vega et al., 2004).
However, expression of PKD is notably reduced in adult myocytes compared to
the neonates (Haworth et al., 2000), thus the impact of PKD on HDAC5
translocation in adult myocytes may differ. Indeed, we previously demonstrated
that ET-1 hypertrophic signaling is predominantly dependent on local IP 3-induced
Ca2+ release and independent of PKC isoforms (Wu et al., 2006). We also
showed that ET-1 mediated HDAC5 nuclear export was contributed equally by
CaMKII and PKD activation (Wu et al., 2006). Here, we report that -agonist, PE,
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induces comparable HDAC5 nuclear export to ET-1, but triggers a different
signaling cascade. PE-induced HDAC5 nuclear export is largely driven by PKC
and PKD activation, but is independent of IP3-CaMKII activation. This prompts
the question of how both Gq-agonists can induce hypertrophic signaling via
nuclear export of HDAC5, but diverge in their activation pathway of two parallel
cytosolic kinases. To dissect the difference in ET-1 and PE mediated signaling
mechanism, we examine in detail the spatiotemporal activation of PKD by these
two Gq-agonists in adult myocytes.
Both ET-1 and PE trigger comparable global PKD activation based on
S916

auto-phosphorylation

and

FRET-based

DKAR

measurements.

Nevertheless, the two Gq-agonists differ in their activation mechanism indicated
by reduced SS744/748 phosphorylation (PKC sites) during ET-1 stimulation
compared to PE (Figure 12). The western blot suggests that ET-1 is capable of
activating PKD without upstream PKC activation. This is consistent with our
previous observation where ET-1 driven HDAC5 nuclear export is partially PKDdependent, but independent of PKC isoforms (Wu et al., 2006).
The classical PKD activation mechanism depicts a PKC-dependent
activation in two sequential phases (Jacamo et al., 2008; Rykx et al., 2003). The
first phase describes initial PKD recruitment to the plasma membrane, along with
upstream PKC, to be phosphorylated by active PKC isoforms at its SS744/748
site. The second phase denotes its subsequent auto-phosphorylation at S916
once PKD itself is catalytically active. Our translocation data (Figure 16 to Figure
19) confirm that both ET-1 and PE are capable of activating PKD in adult cardiac
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myocytes. Notably, ET-1 induced plasma membrane recruitment of PKD is more
prominent and more stable than PE, yet there is higher nuclear PKD
translocation inducible by PE than ET-1. This could be explained in part by the
notion that ET-1 can activate PKD without upstream PKC (Wu et al., 2006) and
results in more stable membrane-bound PKD that associate to other membrane
protein partners. Moreover, the TIRF data collected by Dr. Julie Bossuyt show
similar initial sarcolemmal recruitment rate of PKD by both agonists. While PE
recruits a smaller amount of PKD to the membrane (Bossuyt et al., 2011), its
peak recruitment to the plasma membrane occurs faster than those inducible by
ET-1 and PdBu (Bossuyt et al., 2011). These translocation data are consistent
with the notion that PKC phosphorylation at SS744/748 (as seen during PE
stimulation) facilitates the reverse membrane translocation of PKD to other
intracellular compartments, such as the nucleus (Newton and Johnson, 1998).
Such reverse translocation is unavailable during ET-1 stimulation since PKC
phosphorylation at SS744/748 sites is not required (Figure 12) (Wu et al., 2006),
thus results a more stable membrane-bound PKD.
Recent publication by Wright et al. reports that -adrenergic receptors are
mostly perinuclear (Wright et al., 2008), which can provide an alternative
interpretation of our data where PE-induced lower sarcolemmal recruitment of
PKD is due to the location of -adrenergic receptors. Nevertheless, we did not
observe distinguishable perinuclear PKD localization upon PE stimulation during
our confocal study. In addition, our TIRF data supports the theory that PE, like
ET-1, initiates PKD activation at the sarcolemma, thus is able to produce a rapid

95
reverse membrane translocation to the nucleus as seen in our FRAP study
(Figure 4 and 5 from (Bossuyt et al., 2011)). Overall, these data describes a
mechanism of PKD activation where -adrenergic agonist, PE, initiates PKD
activation near the sarcolemma followed by its rapid translocation to the nucleus.
However, we cannot exclude that some PKD activation upon PE stimulation may
occur near the nuclear envelope.
Our data above also explains why HDAC5 phosphorylation and nuclear
export is predominantly PKD-dependent for PE and not for ET-1. On the other
hand, ET-1 mediated HDAC5 phosphorylation and nuclear export require IP 3CaMKII activation. This is supported by our observation of a slow and smaller
nuclear PKD activation when ET-1 is applied. Although our study has greatly
improved the overall mechanistic understanding of PKD activation in response to
ET-1 and PE in adult myocytes, further study will be needed to answer the
following questions. First, what are the molecular protein partners near the
sarcolemma to allow rapid reverse translocation of PKD during PE stimulation or
to encourage membrane-associated PKD in response to ET-1? What is the PKCindependent mechanism of PKD activation during ET-1 treatment (in contrast to
PE)? Other studies have previously reported some PKC-independent activation
of PKD (Jacamo et al., 2008; Rozengurt et al., 2005; Wang, 2006), but they
exhibit a different temporal scale. Lastly, since PE can trigger IP 3 and DAG
production similarly to ET-1, what prevents the PE-induced IP3 from reaching
intracellular IP3 receptors to induce CaMKII activation? Although there are
questions remain to be answered, our study provides valuable information
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regarding the agonist-specific differential activation of CaMKII and PKD to
phosphorylate and mediate HDAC5 nuclear export by ET-1 and PE respectively.
An important aspect of our findings point to the difference in global vs.
local PKD activation. For example, all three hypertrophic agonists, ET-1, PE and
PdBu induce global PKD activation via S916 phosphorylation and DKAR
measurements. Targeted DKAR at the membrane also demonstrate similar near
maximal PKD activity upon ET-1, PE and PDBu stimulation. This suggests that
even with a small portion of PKD recruitment at the membrane, PE is able to
elicit comparable PKD activation here (compared to stronger membraneassociated PKD seen with ET-1 and PDBu treatments).
Moreover, nuclear PKD import and activation is faster and larger under PE
treatment than ET-1 based on our confocal and Nuc-DKAR experiments. Yet, a
moderate amount of nuclear activation PKD is sufficient to phosphorylate nuclear
HDAC5 and mediate its export during ET-1 stimulation when CaMKII is inhibited
(Figure 15). Furthermore, PKD may have additional functions in the cytosol to rephosphorylate HDAC5 and keep it cytosolic longer (as shown for CaMKII) (Zhang
et al., 2007).
In conclusion, our current study highlights the differential dynamic
spatiotemporal activation of PKD in response to important Gq-agonists, ET-1 and
PE. The findings here support the notion that PKD, as an emerging cardiac
kinase, is subject to cellular fine-tuning regulatory mechanism. Specifically, its
global activation can differ greatly from its local activation in many intracellular
compartments, such as the plasma membrane and the nucleus. Therefore,
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inhibition of PKD activity may be an attractive therapeutic target in the future due
to its role in modulation of transcriptional repressor, HDAC5, in adult cardiac
myocytes.

Chapter 5
AIM 2

“Acute -adrenergic Activation Triggers Nuclear Import of Histone Deacetylase 5
and Delays Gq-induced Transcriptional Activation”

Introduction
Histone deacetylases (HDACs) are transcriptional repressors crucial to the
regulation of gene transcription and key transducers of extracellular stimuli that
impact genetic programming (Backs and Olson, 2006; Johnson and Turner,
1999). As epigenetic regulators, HDACs interact with multitude of transcriptional
factors to regulate gene transcription or repression, thus have important
implications in disease and development (Haberland et al., 2009; Martin et al.,
2007). The functional role of HDAC is typically achieved by removing acetyl
groups from histone tails to suppress transcriptional activation, thereby
antagonizing the action of histone acetyl transferases (HAT), which promotes
transcription via acetylation (Backs and Olson, 2006; Bush and McKinsey, 2009;
McKinsey and Olson, 2005).
To date, with 18 identified mammalian isoforms, the HDAC superfamily is
divided into 4 distinct classes (class I, II, III and IV) with a relatively conserved
98
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catalytic domain (Haberland et al., 2009; Parra and Verdin, 2010; Yang and
Gregoire, 2005) Compared to other subtypes, class II HDACs (4, 5, 6, 7, 9 and
10) exhibit tissue-specificity with predominant expression in skeletal muscles,
heart, brain and T-cells while class I and III are found more ubiquitously
expressed in other cell types (Bertos et al., 2001; Calalb et al., 2009; Parra and
Verdin).

Like other class IIa members, HDAC5 contains a catalytic

deacetylase domain in the C-terminal half between a NLS at the N-terminus and
a NES near the C-terminus. Many in vivo studies have examined the functional
role of HDAC5 in the heart and its consequent stress-induced exacerbated
cardiac hypertrophy in knockout mice with a loss-of-function phenotype (Chang
et al., 2004; Haberland et al., 2009; Kee and Kook), highlighting the importance
of its cellular localization and function in regulating cardiac physiology and
pathology. Specifically, fundamental regulation of HDAC5 is crucial to cardiac
remodeling and hypertrophy at the cellular level, where activation of the “fetal
gene program” is initiated by relieving transcriptional inhibition to activate MEF2
controlled genes (Lu et al., 2000b; Martin et al., 2009; McKinsey et al., 2000a;
McKinsey et al., 2000b; McKinsey et al., 2002).
Compelling evidence has established that HDAC5 nucleocytoplasmic
shuttling is highly regulated by its phosphorylation at S259 and S498 to initiate its
phosphorylation-dependent nuclear export via binding to 14-3-3 chaperone
proteins and unmasking its NES signal (Ellis et al., 2003; Grozinger and
Schreiber, 2000; Harrison et al., 2004; McKinsey et al., 2000b; McKinsey et al.,
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2001; McKinsey et al., 2002). Accordingly, we and others have reported that
neurohumoral stress stimuli coupled to activation of G-protein receptors can
trigger downstream target kinases, such as CaMKII, PKC and PKD to
phosphorylate HDAC5 at these sites and mediate its nuclear export in cardiac
myocytes (Bossuyt et al.; Bossuyt et al., 2008; Harrison et al.; Harrison et al.,
2006; Vega et al., 2004; Wu et al., 2006). The dynamic shuttling of HDAC5
between the nucleus and the cytosol has been investigated due to its specific
expression and function in cardiac myocytes, yet detailed mechanism of its
regulated trafficking remains to be elucidated, especially during activation of
multiple stress stimuli.
Neurohumoral signaling has uncovered several class II HDAC kinases
that can mediate de-repression of MEF-2 dependent genes via nuclear export of
HDAC5. There is little information about the cross interaction of neurohumoral
signaling with -AR activation, a major pathway involved in sympathetic
stimulation that can improve cardiac functions acutely but can also trigger
pathological cardiac remodeling and heart failure under chronic activation
(Chidsey et al., 1963; Movsesian and Bristow, 2005). There are several studies
investigating the role of PKA activation on hypertrophy signaling, but the pathway
is unclear. For example, PKA has been reported to facilitate PKD activation and
mobilize the consequent hypertrophic signaling due to their common association
with scaffolding protein, AKAP-Lbc, in Cos7 cells and neonatal rat ventricular
myocytes (NRVM) (Appert-Collin et al., 2007; Carnegie et al., 2004; Carnegie et
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al., 2008). Alternatively, PKA has recently been identified to modulate MEF-2
regulated

gene

expression

by

promoting

proteolysis

of

HDAC4

and

phosphorylating HDAC5 directly exerting anti-hypertrophic effect against stress
stimuli in HEK cells, Cos7 cells and NRVM (Backs et al., 2011; Ha et al., 2010;
Sucharov et al., 2011). These biochemical and enzymatic experiments show
results that are mostly described in immortal cell lines and neonatal myocytes,
both provide very different cellular environment from adult myocytes. Thus, the
role of PKA activation on hypertrophic signaling remains to be clarified, especially
in adult cardiac myocytes.
In this study, we investigate the effects of -AR signaling and PKA
activation on regulation of nucleocytoplasmic HDAC5 shuttling and its cross
interaction with Gq-driven hypertrophic signaling in adult ventricular myocytes.
We focus on contrasting the effects of acute vs. chronic -AR stimulation since
chronic -AR stimulation also triggers maladaptive changes leading to
hypertrophy and is associated with decreased cardiac function (Chidsey et al.,
1963; Movsesian and Bristow, 2005). We report that acute ISO and forskolin
treatments promote strong nuclear HDAC5 accumulation in contrast to the
nuclear export during Gq-agonist stimulation. Thus, acute PKA activation
protects against Gq-driven HDAC5 nuclear export and hypertrophic signaling.
Prolonged forskolin treatment results in further enhancement of nuclear HDAC5
signal, yet permits the subsequent Gq-mediated HDAC5 nuclear export. Heart
failure rabbit myocytes exhibit a more cytosolic HDAC5 distribution with an
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absence of ISO-induced HDAC5 nuclear accumulation, demonstrating blunted AR sensitivity in heart failure cells and reduced gene repression control. In
summary, this study provides insights to cross-interaction between -AR and Gq
signaling pathways at the level of gene transcriptional control via regulating
HDAC5 shuttling between nucleus and cytosol in adult cardiac myocytes.
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Materials and Methods
Adenoviral Generation
WT HDAC5, S279A and S279D variants were subcloned into a pShuttleCMV vector by restriction enzyme digestion and ligation. Using the AdEasy
Adenoviral Vector System (Agilent), HDAC5-GFP adenoviral DNA was generated
and prepared by Wizard Plus Miniprep DNA Kit (Promega). HEK cells plated at
90% confluence on 6 cm culture dishes was transfected with GFP-tagged
HDAC5 adenoviral DNA (10 g) using Polyfect transfection reagent (Qiagen) in 2
mL of growth medium supplemented with 3% penicillin/streptomycin and 2% FBS
(CellGro). After 2 weeks of plaque formation, lysed cells were harvested and
centrifuged at 2,000 rpm for 3 min. The supernatant was then transferred onto 10
cm culture dishes plated with HEK cells at 90% confluency. Upon completion of
cell lysis, adenovirus DNA was further amplified by transferring to thirty 10 cm
dishes. Cells were harvested, lysed by freeze-thaw cycles (3 times), and purified
using a cesium chloride gradient method. The mature adenovirus particles were
then extracted and dialyzed in Slide-A-Lyzer Dialysis cassette (Thermo Scientific)
in 1x PBS at 4oC overnight. The next day, the purified adenovirus was aliquoted
and stored at -80oC.
Cell Isolation and Culturing
We isolated ventricular myocytes from adult New Zealand white rabbit
(male, average age of 3.5 months, average weight of 2.2 kg and purchased from
Charles River Laboratories) as described previously (Bassani et al., 1994). All
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animal procedures were performed in accordance to Institutional Animal Care
Use Committee regulations at University of California-Davis. Isolated myocytes
were allowed to settle by gravity and re-suspended in PC-1 medium (Lonza)
supplemented with 5% penicillin/streptomycin. 2-well glass coverslips were
coated with laminin (Invitrogen) and allowed to air-dry prior to plating. 2 mL of cell
resuspension was added to each well of the coverslip and incubated at 37 oC for
45 min for attachment. Cells were gently washed and incubated with fresh PC-1
medium immediately before adenoviral infection with GFP-tagged constructs of
WT HDAC5, SS259/498AA, S279A and S279D at 37oC overnight (multiplicity of
infection at 10-100).

Confocal Imaging
Coverslip was placed on an inverted microscope (Zeiss, LSM5 Pascal or
Olympus) equipped with 40x water immersion object lens. Argon laser (3-5%)
was used to excite GFP at 488 nm, and emission wavelength was collected with
long-pass filter above 505 nm. PC-1 medium was replaced with normal tyrode
solution containing 1.8 mM Ca2+ before each experiment. Cells were imaged
before and after treatment with agonists, such as ET-1 (100 nM), PE (20 M),
ISO (100 nM) or forskolin (10 M) for 1 hr. NIH Image J software was used for
image analysis. The nucleus was traced with ROI to measure its fluorescence
intensity and divided by the average of three randomly selected ROIs of equal
size in the cytoplasm to compare the nuclear vs. cytosolic signal. Each F nuc/Fcyto
ratio was normalized to initial time point for comparison between different groups.
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Heart Failure Animal Model
Heart failure was induced in adult New Zealand White rabbit as described
previously (Pogwizd et al., 1999). Briefly, HF was induced by two sequential
survival surgeries by first inducing aortic insufficiency and followed with aortic
constriction after 2-8 weeks post-op monitoring. Each rabbit was monitored with
echocardiogram to determine the severity of the HF status (typically 4-6months)
and scheduled for isolation procedure accordingly.

Co-immunoprecipitation (Co-IP)
Isolated adult rabbit myocytes were infected with GFP-tagged WT and
S279A constructs of HDAC5 and cultured overnight in PC-1 media (Lonza)
(multiplicity of infection = 10-100). Next day, myocytes were treated with or
without ISO (100 nM) for 20 min prior to addition of ET-1 (100 nM) for 1 hr. Cells
were scraped, pelleted at 2,000 rpm for 3 min and supernatant was removed.
Control and treated pellets were frozen in liquid nitrogen and then were lysed
with IP buffer (pH = 7.4 containing 25 mM Tris-HCl, 150 mM NaCl,1 mM EDTA, 2
mM EGTA, 1% NP-40, 1 mL phosphatase inhibitor cocktail set III (Calbiochem),
1 mL protease inhibitor cocktail set III (Calbiochem)). Cell lysates were resuspended and incubated on ice for 30 min. Cell debris was pelleted using a
hand centrifuge for 1 min, and supernatant was collected to determine protein
concentration using BCA kit (Thermo Scientific). 200 g of protein from each
sample was incubated end over end with GFP antibody conjugated with agarose
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beads (Santa Cruz Biotechnology, sc-9996 AC) in 3 mL of IP buffer at 4oC
overnight. The next day, samples were centrifuged at 2,000 rpm for 3 min and
washed 3 times with washing buffer (pH = 7.4 containing 25 mM Tris-HCl, 150
mM NaCl, 1 mM EDTA, 2 mM EGTA, 1 mL phosphatase inhibitor cocktail set III
(Calbiochem), 1 mL protease inhibitor cocktail set III (Calbiochem)). IP pellets
were collected for probing levels of 14-3-3 binding to WT HDAC5-GFP or S279AGFP using immuno-blots.

Western Blotting
Adult rabbit or rat ventricular myocyte samples added with Laemmli
sample buffer were heated at 95oC for 5 min prior to loading onto SDS-PAGE
gels (Biorad), and subject to electrophoresis at 90V for 2 hr. Proteins were
transferred onto nitrocellulose membrane overnight at 20V for 12 hr. The next
day, nitrocellulose membranes were blocked with 8% milk in Tris-buffered saline
solution (TBS) with 0.2% Tween followed by incubation with primary antibody
overnight at 4oC. The primary antibodies used for immunoblotting were diluted in
TBST as follows: rabbit GFP antibody (1:10,000) from Abcam, rabbit pan 14-3-3
antibody (1:1000) from Santa Cruz Biotechnology, rabbit HDAC5 total (1:2000)
from Signal Antibody Technology, rabbit phospho-HDAC5 Ser498 (1:2000) from
Signal Antibody Technology and mouse GAPDH (1:30,000) from Abcam. The
next day, membranes were washed five times with TBS/TBST and incubated
with secondary goat anti-rabbit or anti-mouse antibody (1:2000 + 0.2% milk)
(Thermo Scientific) for 2 hours at room temperature. After five repetitive washing,

107
membranes were developed using Super Signal West Dura (Thermo Scientific)
and digitally captured with ImageReader LAS-4000. Densitometry analysis was
performed using NIH Image J software.

Luciferase Assay
Isolated rabbit ventricular myocytes were infected with myocyte enhancer
factor-2 (MEF2) luciferase reporter and cultured at 37 oC overnight. The next day,
cells were treated with ET-1, PE, ISO or forskolin for 2 hr. Some myocytes were
also pretreated with ISO or forskolin for 20 min prior to treatment with ET-1 or PE
for 2 hr. The cells were collected, pelleted at 2,000 rpm for 2 min and
supernatant was aspirated. The Dual-Luciferase Reporter Assay (Promega,
catalog E1910) was used for this assay. All reagents were prepared according to
manufacturer’s instructions. 100 l of 1x passive lysis buffer (Promega) was
added to each tube to resuspend the pellet by vortexing. The cell lysates were
transferred to 1.5 mL of eppendorf tubes and centrifuged at 25,000 rpm for 5 min.
To begin luciferase assay, 20 l of passive lysis buffer lysate/well of each sample
was added to the 96-well white costar plate with opaque bottom. (Each sample
was prepared as duplicates for luciferase assay.) 40 l of both luciferase
substrate with buffer and Stop & Glo substrate with buffer were required for each
sample. Total amounts of both reagents were calculated and prepared in
separate falcon tubes covered with aluminum foil. The 96-well plate, luciferase
reagent and renilla reagent were all placed in the Veritas luminometer. The assay
was performed using Veritas software to measure firefly luciferase activity
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followed by renilla luciferase activity. Cardiac myocytes do not possess
endogenous renilla reporter, thus the renilla luciferase readouts are used and
subtracted as background fluorescence. All treatments were normalized to
amount of protein content and control (untreated sample) for each experiment.

Statistical Analysis
Pooled data are represented as mean + SEM. We performed student’s ttest or one-way analysis of variance (ANOVA) with Bonferroni post hoc test when
applicable and p<0.05 was considered statistically significant.
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Results

-AR signaling via PKA induced HDAC5 nuclear accumulation in contrast
to Gq-mediated signaling
To study the intracellular translocation of HDAC5 in isolated adult rabbit
ventricular myocytes, we used a GFP-tagged HDAC5 construct displaying
predominant nuclear expression (Figure 24). We compared the ET-1 mediated
nuclear export of HDAC5 and ISO induced nuclear accumulation of HDAC5 at 1
hour. As shown in Figure 31, -AR agonist, ISO, induced a strong accumulation
of HDAC5-GFP in the nucleus (Fnuc/Fcyto = 1.33 + 0.03) in contrast to the nuclear
depletion mediated by Gq-agonists, ET-1 (Fnuc/Fcyto = 0.76 + 0.01) or PE
(Fnuc/Fcyto = 0.79 + 0.01) at 1 hour (Figure 25). Since PKA is a known
downstream effector of -AR signaling, we tested the hypothesis that the effect of
HDAC5 nuclear accumulation is mainly triggered by PKA. Thus, we used
forskolin, an adenyl cyclase activator to activate PKA, and this resulted in
increased nuclear HDAC5 accumulation similar to ISO, but to a slightly lesser
degree (Fnuc/Fcyto = 1.23 + 0.04). Figure 26 summarizes the results of HDAC5GFP translocation at 1 hour post-treatment in response to various stimuli. ISO
and forskolin increased nuclear accumulation of HDAC5 by 31% + 2.5% and
17% + 3.5% respectively, while Gq-agonists, ET-1 and PE, mediated comparable
nuclear export of HDAC5 (Fnuc/Fcyto = 0.68 + 0.03 for ET-1; Fnuc/Fcyto = 0.71 +
0.04 for PE). Furthermore, figure 27 shows that 20 min pre-inhibition of PKA with
H89 (10 M) or PKI (36 M) effectively blocked the PKA-mediated
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nuclear accumulation under ISO treatment. ISO-induced nuclear accumulation of
HDAC5 was significantly reduced by 81.1% + 6.3% with H89 pretreatment
(p<0.05) and by 82.6% + 2.1% with PKI (p<0.05). The inhibition of ISO-induced
effect on HDAC5 accumulation in the nucleus by these two PKA inhibitors
confirms that PKA is the major kinase involved in the -AR signaling induced
HDAC5 nuclear import.
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Figure 24. ET-1 induces WT HDAC5-GFP nuclear export while ISO triggers
nuclear import. Representative confocal images of HDAC5-GFP expression in
rabbit adult ventricular myocytes at baseline, pre- and post- treatments with ET-1
(100 nM) or ISO (100 nM) after 1 hr.
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Figure 25. -AR signaling induces nuclear import of HDAC5 in contrast to
Gq-mediated export. HDAC5-GFP translocation data expressed as normalized
Fnuc/Fcyto in response to ISO (100 nM), forskolin (10 M), ET-1 (100 nM) and PE
(20 M) over the course of 60 min.
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Figure 26. -AR signaling induces nuclear import of HDAC5 in contrast to
Gq-mediated export. Bar graph summarizes HDAC5-GFP translocation at 1 hr
post-treatment with ISO (100 nM), forskolin (10 M), ET-1 (100 nM) and PE (20
M). * p< 0.05.
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Figure 27. ISO induced nuclear import of HDAC5 is mainly triggered by
PKA activity. WT HDAC5-GFP translocation induced by ISO (100 nM) treatment
alone or with 20 min pre-incubation of PKA inhibitors, H89 (10 M) or PKI (36
M). * p< 0.05.
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14-3-3 chaperone binding sites are crucial for Gq-mediated but not for  -AR
or PKA-induced HDAC5 translocation
Several studies have established that serine 259 and 498 (S259/S498) of
HDAC5

are

phosphorylated

by CaMKII, PKC or PKD to trigger its

phosphorylation-dependent nuclear export during hypertrophic signaling (Bossuyt
et al., 2008; Harrison et al., 2006; Harrison et al., 2004; Vega et al., 2004; Wu et
al., 2006). Phosphorylation at these two residues is important for binding with
chaperone protein, 14-3-3, to initiate its nuclear export (Figure28) (Ellis et al.,
2003; Grozinger and Schreiber, 2000; Harrison et al., 2004; McKinsey et al.,
2000b; McKinsey et al., 2001). We tested whether these two serine residues are
also involved in nuclear accumulation of HDAC5 induced by -AR signaling or
PKA activation. We used a GFP-tagged HDAC5 mutant with alanine substitution
at these residues (SS259/498AA) to study the importance of these sites in AR/PKA signaling and HDAC5 translocation. The SS259/498AA mutant also
displayed predominant nuclear localization although baseline level of HDAC5
nuclear localization was 31% + 8% higher compared to the WT (Figure 29). This
higher basal nuclear expression was likely due to the total absence of serine
phosphorylation of the SS259/498AA mutant by CaMKII or PKD, thus disrupting
the basal HDAC5 shuttling between the nucleus and the cytosol and preventing
its phosphorylation-dependent nuclear exports at baseline. The implication is that
physiologically, there may be some finite level of baseline phosphorylation at
these sites.
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The non-phosphorylatable mutant SS259/498AA significantly reduced the
HDAC5 nuclear export induced by ET-1 or PE compared to WT (Figure 30).
Conversely, the SS259/498AA mutant did not perturb the ISO or forskolininduced nuclear import (Figure 30), suggesting that the PKA-induced nuclear
accumulation effect of HDAC5 must occur at site(s) different from S259 and
S498. Taken together, the 14-3-3 chaperone binding sites are crucial for the Gqmediated nuclear export mechanism, but are not important for the -AR or PKAinduced HDAC5 accumulation in the nucleus.
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Figure 28. S259 and S498 sites of HDAC5 are crucial for Gq-mediated
phosphorylation and consequent 14-3-3 nuclear export. Schematic diagram
of HDAC5 domains and its phosphorylation sites by CaMKII and PKD for 14-3-3dependent nuclear export mechanism.
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Figure 29. Non-phosphorylatable SS259/498AA mutant results in higher
baseline HDAC5 nuclear localization. Comparison of absolute baseline
localization Fnuc/Fcyto of WT HDAC5 vs. SS259/498AA mutant overexpression in
adult cardiac myocytes. ** p<0.01.
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Figure 30. 14-3-3 chaperone binding sites are crucial for Gq-mediated but
not for -AR or PKA-induced HDAC5 translocation. Bar graph comparison of
GFP-tagged HDAC5 SS259/498AA mutant translocation vs. WT HDAC5 at 1 hr
post-treatment with indicated agonists (ET-1 = 100 nM, PE = 20 M, ISO = 100
nM, FSK = 10 M). * p< 0.05.
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S279 phosphorylation by -AR and PKA stimulation induce HDAC5 nuclear
accumulation
Recently, serine 279 (S279) within the NLS region of HDAC5 was
identified to be directly phosphorylated by PKA (Ha et al., 2010). To test that AR or PKA activation mediates its inhibitory effects on HDAC5 nuclear export
predominantly via phosphorylation of S279, we designed an adenoviral construct
of GFP-tagged HDAC5 mutant with alanine substitution at S279 (S279A) to study
its translocation under -AR/PKA signaling. Baseline expression of the GFPtagged HDAC5 S279A mutant showed similar nuclear targeting compared to WT
(Figure 31), indicating that baseline nucleocytoplasmic shuttling of S279A
remained intact. This result was significantly different from the basal expression
observed with the SS259/498AA mutant where basal shuttling was disturbed by
preventing the phosphorylation at S259 and S498 sites, thus favoring nuclear
retention of HDAC5 (Figure 29). So basal phosphorylation at S279 site may be
negligible.
The GFP-tagged S279A mutant of HDAC5 completely ablated the ISO
and forskolin-induced nuclear import while export remained intact under ET-1
and PE stimulation over 1 hour (Figure 32). Grouped data summarize S279A
translocation at 1 hour post-treatment, where ET-1 or PE-mediated nuclear
export was comparable to WT, while ISO or forskolin induced nuclear
accumulation was completely abolished (Figure 33). These data suggest that
S279 serves as a major site for PKA phosphorylation during -AR signaling
induced HDAC5 nuclear import in adult cardiac myocytes.
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Figure 31. S279A mutant has similar baseline localization compared to WT
HDAC5. Comparison of absolute baseline Fnuc/Fcyto of HDAC5 between WT vs.
S279A variant overexpression in adult cardiac myocytes.
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Figure 32. S279A mutant blocks nuclear import induced by -AR or PKA
activation but responds to Gq-mediated export. Response of GFP-tagged
HDAC5 S279A translocation in response to ISO (100 nM), forskolin (10 M), ET1 (100 nM) and PE (20 M) over 60 min.
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S279 phospho-mimetic mutant inhibits HDAC5 translocation
To test the hypothesis that phosphorylation at S279 prevents nuclear
export inducible by ET-1 or PE, we designed a phosphomimetic HDAC5 mutant
with an aspartic acid substitution at S279 (S279D). Notably, the GFP-tagged
S279D phosphomimetic HDAC5 resulted in 49.9% + 8.7% increase in basal
Fnuc/Fcyto ratio compared to WT. This indicates that the S279D was an effective
phosphomimetic mutant at baseline, giving similar Fnuc/Fcyto ratio as the maximal
ISO or forskolin induced nuclear accumulation of WT HDAC5 (Figure 34).
The GFP-tagged S279D phosphomimetic mutant also completely
prevented ET-1 or PE triggered nuclear export, suggesting that phosphorylation
at S279 site reduces the amount of nuclear export inducible by Gq-agonists
(Figure 35). Moreover, forskolin had no further effect on S279D mutant HDAC5
translocation, indicating that this phosphomimetic mutant was able to completely
abolish the PKA-effects on HDAC5 nuclear accumulation (Figure 35-36).
Intriguingly, we still observed slight nuclear import of HDAC5 by 10% upon ISO
stimulation compared to forskolin. This minor increase suggests that there could
be additional PKA-independent effects on HDAC5 translocation during -AR
stimulation by ISO. In summary, the phosphomimetic mutant significantly
reduced the nuclear export induced by ET-1 or PE, and the HDAC5 nuclear
import induced by ISO and PKA (Figure 36). Therefore, -AR or PKA mediates
HDAC5 nuclear accumulation predominantly via phosphorylation of S279, and
S279 phosphorylation of HDAC5 effectively attenuates the Gq-induced nuclear
export.
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Acute -AR or PKA activation blocks Gq-mediated HDAC5 nuclear export
Since PKA seems to drive HDAC5 import via S279 phosphorylation and
Gq activation (via PKD and CaMKII) drive nuclear export via phosphorylation at
S259 and S498, it is of interest to see which direction dominates HDAC5
translocation upon co-activation. Based on our mutant studies, we hypothesized
that the PKA effect will dominate. To test our hypothesis, we examined the
effects of -AR signaling on Gq-mediated HDAC5 translocation between the
nucleus and the cytosol. Acute PKA pre-stimulation by forskolin for 20 min
abolished the nuclear export of HDAC5 induced by ET-1 or PE treatment (Figure
37). Acute -AR activation with ISO followed by Gq-agonists also effectively
blocked the HDAC5 nuclear export that is inducible by ET-1 or PE. Additionally,
ISO caused ET-1 and PE to trigger slightly more nuclear accumulation. This
again points to the notion that -AR may have a PKA-independent effect to favor
HDAC5 nuclear localization (vs. forskolin). Therefore, acute pre-stimulation of
ISO or forskolin completely prevented the subsequent Gq-agonists mediated
effects on HDAC5 shuttling, indicating that acute -AR stimulation via PKA may
suppress the Gq-driven HDAC5 nuclear export.
To further test whether the -AR stimulation or PKA activation can prevent
or limit HDAC5 S498 phosphorylation in response to Gq activation, we probed for
S498 phosphorylation of endogenous HDAC5 in adult rat myocytes. We used rat
instead of rabbit myocytes for this experiment to minimize non-specific detection
of the primary rabbit polyclonal HDAC5 antibody that is commercially available.
Our results showed that hypertrophic agonists, ET-1, PE and phorbol 12,13-
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dibutyrate (PdBu) all enhanced S498 phosphorylation compared to untreated
control (Figure 38). Conversely, HDAC5 S498 phosphorylation was reduced
under ISO or forskolin stimulation, and 20 min pretreatment of forskolin
effectively abolished endogenous HDAC5 S498 phosphorylation induced by ET1, PE and PdBu. Additionally, co-immunoprecipitation with GFP antibody enables
us to detect the levels 14-3-3 binding with HDAC5-GFP during -AR/PKA and Gq
activation (Figure 39). ET-1 increases the amount of 14-3-3 associated with WT
HDAC5-GFP, but this effect is abolished by 20 min ISO pretreatment. Notably,
ISO treatment alone slightly reduced 14-3-3 association with HDAC5-GFP, in
agreement with the higher nuclear localization seen in this condition. In contrast,
when the PKA resistant S279A HDAC5-GFP was used, ISO did not perturb basal
14-3-3 association and failed to prevent ET-1 induced 14-3-3 binding.
We also examined the effects of -AR/PKA on MEF2-dependent
transcriptional activity in adult cardiac myocytes to test whether the -AR/PKA
effects on HDAC5 translocation resulted in transcriptional regulation. Figure 40
shows that Gq-agonists, ET-1 and PE, promoted MEF2 luciferase activity, while
ISO and forskolin failed to alter basal luciferase activity. Pre-incubation of ISO
and forskolin, however, effectively abolished Gq-agonist induced increases
MEF2 activity. This parallels our confocal studies where -AR/PKA preactivation blocks subsequent Gq-driven HDAC5 nuclear export.
The data suggest that ISO and forskolin treatments diminish basal S498
phosphorylation of endogenous HDAC5, an indicator of its nuclear export
shuttling. Moreover, acute PKA activation reduces S498 phosphorylation of
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HDAC5 during hypertrophic agonist stimulation, thereby promoting HDAC5
nuclear retention. Co-immunoprecipitation data confirm that the ET-1 enhanced
WT HDAC5 interaction with 14-3-3, and this interaction was prevented by preincubation of ISO. HDAC5 S279A mutant, lacking the PKA phosphorylation site,
relieves the ISO inhibitory effect on ET-1-induced 14-3-3 binding. MEF2dependent luciferase activity is promoted by Gq-agonist, but this transcriptional
activation can be effectively abolished with pretreatment of ISO or forskolin.
Therefore, -AR and PKA activation can modulate Gq-mediated HDAC5
translocation via S279 phosphorylation, thus reducing phosphorylation at S498
and precluding binding to 14-3-3 chaperone. Consequently, the Gq-driven MEF2
transcriptional activity can be blocked with acute -AR/PKA activation, indicating
that HDAC5 nuclear export is necessary for relieving the HDAC5 repression on
MEF2-dependent transcriptional control in adult cardiac myocytes.
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Figure 40. -AR or PKA pre-activation inhibits Gq-agonist-induced
hypertrophic MEF2 transcriptional activation. MEF2-dependent luciferase
assay measuring myocyte transcriptional activity in response to agonist
treatment. ***<0.001. (n=5).
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Chronic forskolin exposure enhances HDAC5 nuclear accumulation
Chronic -AR activation is associated with hypertrophy and cardiac
remodeling, whereas we observe that acute -AR and PKA stimulation prevent
the hypertrophic agonist-induced HDAC5 shuttling. To further study the
mechanism of acute vs. chronic PKA signaling, we studied the effects of 24-hr
forskolin exposure on baseline HDAC5 nucleocytoplasmic shuttling. Confocal
images of HDAC5-GFP expression after 24-hr treatment with forskolin are
illustrated in figure 41. Figure 42 shows that prolonged forskolin exposure
increased the nuclear accumulation of HDAC5 by 1.6-fold (Fnuc/Fcyto= 10.27+0.89
vs. Fnuc/Fcyto= 6.33+0.31, p<0.0001 after 1 hour forskolin exposure). Our acute
studies suggest that ISO and PKA-induced HDAC5 nuclear import is mediated
predominantly via S279 phosphorylation. To test whether HDAC5 S279
phosphorylation is also crucial to the prolonged forskolin-mediated nuclear
accumulation, we evaluated the effects of 24-hr forskolin exposure on the
nucleocytoplasmic shuttling of WT HDAC5, S279A and S279D. Figure 43
showed that prolonged forskolin treatment caused significant further increase of
WT HDAC5 in the nucleus while the S279A and S279D mutants both completely
eliminated the increase, suggesting that prolonged forskolin-induced continuous
nuclear import of HDAC5 also occurs in a S279 phosphorylation-dependent
manner.
Next, we assessed if chronic forskolin treatment can inhibit Gq-induced
nuclear export in myocytes treated with forskolin for 24 hr prior to addition of ET1 or PE. Results in figure 44 showed that 24-hr forskolin pretreatment did not
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block the HDAC5 nuclear export triggered by either ET-1 or PE, opposite to that
seen for acute -AR/PKA stimulation. Our data provide evidence that prolonged
forskolin exposure causes further increase of nuclear HDAC5-GFP signal that is
dependent on its S279 phosphorylation. However, chronic forskolin pretreatment
does not block the Gq-mediated HDAC5 nuclear export, in contrast to the
inhibitory effect by acute -AR and PKA activation.
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Figure 41. Chronic forskolin treatment results in further increase in nuclear
WT HDAC5 localization. Representative confocal images of cultured adult rabbit
ventricular myocytes expressing WT HDAC5-GFP as control or treated with
forskolin for 24 hr.
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Absence of ISO-induced HDAC5 nuclear import in HF rabbit myocytes
Our current study demonstrates that acute -AR or PKA activation can
counter Gq-driven transcription activation by preventing nuclear export of
HDAC5. We postulate that the acute ISO/PKA-induced HDAC5 nuclear
accumulation is altered in HF because of the well-documented hyper-adrenergic
state in HF (Port and Bristow, 2001). To validate our hypothesis, we examined
the HDAC5 translocation in HF rabbit myocytes using adenoviral construct of
GFP-tagged WT HDAC5. HF myocytes showed a more cytosolic HDAC5
expression resulting in lower baseline Fnuc/Fcyto ratio as previously reported
(Bossuyt et al., 2008), indicating a decrease in nuclear HDAC5 localization and
gene repression (Figure 45). Treatment with ISO for 1 hr did not trigger HDAC5
nuclear accumulation in these HF myocytes (vs. control) while ET-1 and PE still
induced modest nuclear export (Figure 46). Moreover, pre-incubation of ISO did
not block the following HDAC5 export mediated by ET-1 or PE in HF myocytes
(Figure 47), consistent with data in Figure 44 where prolonged forskolin
treatment did not prevent subsequent Gq-induced HDAC5 export. In summary,
the HDAC5 nuclear import induced by acute -AR stimulation is abolished in HF
myocytes, along with a loss of protective effects against Gq-mediated
hypertrophic response (as was seen for 24-hr forskolin).
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Figure 46. Absent of ISO-induced HDAC5 nuclear accumulation in HF rabbit
myocytes. GFP-tagged WT HDAC5 translocation in response to ISO (100 nM),
ET-1 (100 nM) and PE (20 M).
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Figure 47. Inhibitory effect of ISO on Gq-mediated nuclear export is absent
in HF myocytes. GFP-tagged WT HDAC5 translocation at 1 hr post-treatment
with 20 min pre-incubation of ISO (100 nM) followed by addition of ET-1 (100 nM)
or PE (20 M) for 1 hr.
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Discussion
The current study highlights the physiological cross interactions between
-AR and Gq-driven signaling at the level of HDAC5 shuttling in adult cardiac
myocytes which is important because hemodynamic stress often induces coactivation of both systems. We report that acute -AR stimulation or PKA
activation promotes nuclear accumulation of HDAC5 in contrast to the Gqinduced nuclear export of HDAC5. In addition, acute pretreatment of ISO or
forskolin effectively prevents the Gq-induced HDAC5 nuclear export and would
prevent or delay transcriptional activation in adult cardiac myocytes.
It has been well characterized that S259 and S498 residues of HDAC5 are
the major phosphorylation targets by CaMKII and PKD to initiate the 14-3-3
dependent nuclear export in neonatal and adult myocytes during Gq-driven
hypertrophic signaling (Bossuyt et al., 2008; Grozinger and Schreiber, 2000;
Harrison et al., 2006; McKinsey et al., 2000a; McKinsey et al., 2000b; Vega et al.,
2004). On the other hand, there are conflicting data regarding the role of PKA
activation during hypertrophic signaling, and its pathway remains unclear in adult
myocyotes. Moreover, the fundamental impact of HDAC5 phosphorylation by
PKA in adult myocytes is not well defined.
We present here that the non-phosphorylatable HDAC5 mutant, S279A,
ablates the ISO or forskolin induced HDAC5 nuclear import, but does not perturb
Gq-driven export. Conversely, mimicking phosphorylation at S279 site resulted in
constitutive HDAC5 nuclear import and effectively blocked Gq-induced nuclear
export of HDAC5. Moreover, the constitutive nuclear accumulation of the S279D
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mutant could not be further enhanced by PKA activation. The data suggest that
-AR and PKA activation mediated nuclear translocation of HDAC5 is
predominantly S279 phosphorylation-dependent. Our confocal study of HDAC5GFP translocation in adult myocytes complements recent publications where an
in vitro kinase assay identified PKA as a novel kinase to directly phosphorylate
HDAC5 at S279 in Cos 7 cells and neonatal rat ventricular myocytes (Ha et al.,
2010), and PKA activation negatively regulates 1-adrenergic mediated HDAC5
phosphorylation in neonatal rat ventricular myocytes (Sucharov et al., 2011).
Furthermore, our immunoblot data indicate that forskolin pretreatment
significantly reduces the level of S498 phosphorylation of endogenous HDAC5
inducible by Gq-agonist in adult rat myocytes. This observation is supplemented
by our co-immumoprecipitation results detecting a decreased level of
endogenous 14-3-3 binding to WT HDAC5-GFP in the presence of -AR
activation with Gq-agonist, ET-1. Together, we show that -AR or PKA activation
prevents Gq-induced phosphorylation at S498 and thus attenuates the
consequent 14-3-3 association to prevent its nuclear export. In contrast,
Carnegie et al. has reported that an AKAP-Lbc complex allows PKA activation to
potentiate PKD activation in vitro, thereby facilitating downstream HDAC5
nuclear export in HEK cells (Carnegie et al., 2004; Carnegie et al., 2008). The
discrepancies could be due to the nature of different cell types and the respective
14-3-3 isoforms present to associate with HDACs (Ellis et al., 2003; Faul et al.,
2007; Margariti et al., 2010) Additionally, substrate specificity of cAMP/PKA
signaling is achieved by compartmentalization of localized cAMP gradient via
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phosphodiesterase isoforms or beta arrestins and by association with various
AKAP scaffolding subtypes in different cell types (Berthouze et al., 2011; Diviani
et al., 2011; Dodge-Kafka et al., 2010; Dodge-Kafka et al., 2006; Dodge-Kafka et
al., 2005; Fischmeister et al., 2006; Leroy et al., 2008; Mika et al., 2012; Mongillo
et al., 2004; Mongillo and Zaccolo, 2006; Nikolaev et al., 2006; Perry et al., 2002;
Redden and Dodge-Kafka, 2011). Our study provides real time observation of
HDAC5-GFP translocation in adult myocytes to more accurately reflect the
fundamentally dominant endogenous signaling pathway in adult ventricular
myocytes.
The confocal data are further validated by our experiment of MEF2dependent transcriptional regulation in adult cardiac myocytes. The MEF2dependent transcriptional activity can be upregulated upon Gq activation to
promote hypertrophic signaling. However, acute -AR/PKA activation significantly
blocks the Gq-driven MEF2 activity, indicating that short term -AR/PKA
signaling counters the transcriptional activation induced by neurohumoral stimuli.
Collectively, our data suggest that acute -AR or PKA activation is
protective against the hypertrophic stimulation during Gq-activation, by
preventing nuclear export of HDAC5 in adult myocytes. This has significant
implications in the regulation of cardiac physiology where short term sympathetic
stimulation, such as exercise or fight or flight response, encourages beneficial
compensations

of

increased

cardiac

output

without

triggering

acute

transcriptional changes. The protective effect of -AR/PKA activation provides a
short term window for cardiac myocytes to adjust quickly to external stimuli
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before attempting to re-program its genetic control that is otherwise necessary
during more severe long-term stress conditions.
Chronic catecholamine stimulation is associated with decreased cardiac
function and pathological cardiac remodeling, leading to hypertrophy and heart
failure. While we observe that acute -AR/PKA activation protects against
neurohumoral-induced transcriptional activation, we show that the HDAC5-GFP
nuclear signal is substantially elevated after a 24-hour exposure to forskolin (1.6
fold over 1 hour treatment). While this enhancement of nuclear HDAC5 is also
dependent upon S279 phosphorylation, prolonged forskolin treatment does not
prevent the nuclear HDAC5 export induced by Gq-agonist. Our findings suggest
that S279 phosphorylation by PKA is still important during chronic forskolin
induced elevation of nuclear HDAC5, yet the mechanism of allowing subsequent
Gq-drive nuclear export remains unclear. Although Ha and colleagues identified
PKA as a novel HDAC5 kinase to directly phosphorylate at its S279 site using in
vitro kinase assay, we importantly show the dynamics of this regulation in adult
cardiac myocytes. An additional mechanistic issue remains as to how
intracellular PKA localizes to HDAC5 during the acute or chronic -AR
stimulation to alter HDAC5 translocation and transcriptional activity. One
possibility is that a PKA anchoring proteins (AKAP) could be involved, and that
has been suggested (Carnegie et al., 2004; Carnegie et al., 2008; Diviani et al.,
2011). It will be of future interest to test whether a specific AKAP association is
altered during the acute vs. chronic -AR activation or perhaps the neighboring
proteins associated with PKA are differentially partnered with the AKAP.
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We speculate that chronic PKA activation may recruit additional effects
(e.g. PKA-dependent phosphorylation at additional HDAC5 sites), which restore
the ability of PKD and CaMKII to phosphorylate S259 and S498 to drive HDAC5
nuclear export. This impact of temporal dynamic phosphorylation of HDAC5 on
functional systemic regulation is further supported by a parallel study in rodent
striatum where reduced S279 phosphorylation of HDAC5 during acute cocaine
injection is restored after 24-hr exposure to cocaine (Taniguchi et al., 2012).
Moreover,

a

recent

proteomic

study

indicates

that

HDAC5

contains

approximately 17 conserved serine/threonine sites available for in vivo
phosphorylation (Greco et al., 2011). The impact of additional phosphorylation
sites could alter potential interaction with other protein partners, such as kinases,
phosphatases or scaffolding complex. Hence, we cannot exclude the possibility
that chronic S279 phosphorylation may facilitate phosphorylation at S259/S498
or other sites to permit HDAC5 nuclear export after chronic PKA activation in
cardiac myocytes.
While the mechanistic details of this acute vs. chronic PKA regulation of
HDAC5 translocation will require further study, it represents a novel and elegant
switch that fulfills a key physiological control point. That is, in short-term fight or
flight responses, transcriptional activation by Gq-HDAC5 signaling is held in
check, whereas in chronic PKA-related stress, such repression is relieved. Our
findings in HF myocytes further support this time-dependence regulation of
transcriptional activation where protection against Gq-induced HDAC5 nuclear
export occurs only during acute -AR or PKA activation, and not during sustained
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activation of PKA.
To the extent that HF constitutes a hyper-adrenergic state, one might
expect HDAC5 Fnuc/Fcyto ratio to be elevated. However, in HF, that ratio is
reduced vs. control. This may have two causes: 1) the level of chronic PKA
activation is likely much less in HF than we used experimentally (and
downregulation of 1-AR and elevated phosphatases function could also limit the
PKA effect) and 2) HF is known to be accompanied by elevated levels of
circulating Gq agonists (norepinephrine, ET-1 and angiotensin II). Moreover, ET1 and PE can and do trigger nuclear HDAC5 nuclear export in HF (Figure 46),
possibly attributed to the increased PKD and CaMKII activity in HF (Bossuyt et
al., 2008). The net result is that in HF there is reduced repression by nuclear
HDAC5

of

hypertrophic

gene

transcription

and

retained

sensitivity

to

neurohumoral regulation via Gq-coupled receptor agonists. The dynamic
interplay and opposing effects of -AR vs. Gq-coupled receptors on HDAC5
translocation may be important to consider in the context of -blockers,
angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor
blockers (ARB) in HF. For example, it is possible that acute -blockade alone
could exacerbate Gq-agonist effects in HF and coordinated block of Gq and -AR
signaling (or Gq block first) could most effectively dampen this maladaptive
signaling pathway.
In conclusion, our study demonstrates the physiological interaction
between -AR and Gq-coupled signaling pathway and their regulation on HDAC5
nucleocytoplasmic shuttling in adult cardiac myocytes. We report that acute -AR
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and PKA activation favors HDAC5-dependent transcriptional repression by
blocking neurohumoral activation effects (Figure 48) and provides a time window
for myocytes to adjust to stress stimuli before resorting to epigenetic regulation.
Accordingly, chronic stress such as HF permits neurohumoral signaling mediated
transcriptional activation by relieving HDAC5 transcriptional inhibition. Our
findings illustrate the importance of acute vs. chronic -AR regulation in adult
cardiac myocytes where acute sympathetic signaling is protective against Gqdriven

hypertrophy

while

chronic

stress

promotes

pathological

remodeling via HDAC5-dependent transcriptional regulation.

cardiac
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Figure 48. Working hypothesis in adult cardiac myocytes. Acute -AR/PKA
signaling activates PKA to promote HDAC5 nuclear accumulation and prevent
Gq-drivenHDAC5

nuclear

export

by

S279

phosphorylation.

CHAPTER 6
AIM 3
Introduction
The functional role of PKD in hypertrophic signaling has become
increasing important due to its involvement in many aspects of cardiac
physiology. For instance, PKD is found to alter cardiac contractile function via its
ability to alter Ca2+ sensitivity of myofilament protein phosphorylation (Bardswell
et al., 2010; Cuello et al., 2007; Goodall et al., 2010; Haworth et al., 2004).
Moreover, PKD is also implicated in non-contractile regulation of cardiac
myocytes,

such

as

cardiac

remodeling

and

hypertrophy

via

HDAC

phosphorylation and shuttling (Bossuyt et al., 2011; Bossuyt et al., 2008;
Harrison et al., 2010; Harrison et al., 2006; McKinsey, 2007; Vega et al., 2004).
PKD can also participate in the cardiac immune response by activation of
transcriptional factor, nuclear factor kappa-light-chain-enhancer of activated B
cells (NFB) (Avkiran et al., 2008; Fu and Rubin, 2011; Rozengurt, 2011;
Rozengurt et al., 2005). In particular, constitutively active PKD can trigger cardiac
hypertrophy (Harrison et al., 2006) while cardiac specific PKD knockout mice
exhibit reduced amount of cardiac remodeling in response to TAC-induced
pressure overload (Fielitz et al., 2008). These findings substantiate the
153
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importance of PKD in modulating cardiac pathophysiology and its potential as a
therapeutic target for cardiovascular disease.
The regulatory role of PKD during hypertrophic response and cardiac
remodeling is attributed to its association with transcriptional repressor, HDAC5.
PKD, along with CaMKII, has been reported to mediate direct phosphorylation of
HDAC5 and relieve the transcriptional inhibition on MEF2-dependent genes
(McKinsey and Olson, 2005). This epigenetic modification is absolutely
fundamental to the initiation of “fetal gene program” in adult cardiac myocytes.
This molecular reprogramming occurs as an adaptive response to increased
cardiac demand by neurohumoral or hemodynamic stress to encourage growth in
the terminally differentiated cardiac myocytes. Even with brief initial functional
benefits, the remodeling process eventually deteriorates the cardiac phenotype
and can trigger maladaptive changes in the heart if stress stimuli are prolonged.
Recent interest has been dedicated to study the intracellular activation
mechanism of PKD to explore its potential in future therapy for cardiac disease
due to its unequivocal role in epigenetic re-programming of adult cardiac
myocytes. However, the potential crosstalk interaction between PKD and PKA
signaling pathways remains unclear due to contradicting reports regarding the
effects of PKA signaling on PKD activation. Carnegie et al. and colleagues
demonstrate the positive regulatory role of PKA signaling on PKD activation via
AKAP-Lbc association in cell lines and neonatal myocytes (Carnegie et al., 2004;
Carnegie et al., 2008). In contrast, others studies report a negative modulatory
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role for PKA activity on PKD activation in adult rat myocytes (Haworth et al.,
2011; Haworth et al., 2007). Therefore, the crosstalk interaction between these
two signaling pathways demands further clarification, especially in adult
myocytes.
Accordingly, we and others have recently uncovered the protective effect
of acute -AR/PKA signaling on Gq-driven transcriptional activation via nuclear
accumulation of HDAC5 (Ha et al., 2010; Sucharov et al., 2011). Although PKA is
shown to directly phosphorylate HDAC5 and blocks its nuclear export (Ha et al.,
2010), we hypothesized that an additional mechanism to inhibit HDAC5 nuclear
export is by limiting upstream PKD activity. For instance, PKA can also directly
phosphorylate PKD and alter is translocation and activation patterns. To this end,
we propose to examine the spatiotemporal activation of PKD in adult myocytes
using fluorescent techniques, such as confocal and FRET imaging, in
combination with biochemical approach to compare any differences in -AR/PKA
activation vs. Gq-agonist stimulation. Our initial findings indicate a negative
modulatory role of -AR/PKA signaling in Gq-induced PKD translocation and
activation in adult myocytes.
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Results

-AR and PKA activation negatively modulates Gq-mediated PKD
translocation
We have recently uncovered that -AR and PKA activation can trigger
nuclear accumulation of HDAC5 by directly phosphorylation of S279 and that this
also blocks the Gq-driven HDAC5 nuclear export if followed by ET-1 or PE
treatment (unpublished data). Our data suggest that -AR/PKA signaling is
protective

against hypertrophic response to

Gq-mediated

transcriptional

activation. An additional indirect mechanism by which -AR/PKA might inhibit
HDAC5 nuclear export is by limiting upstream PKD activation to block the
HDAC5 phosphorylation-dependent export. Therefore, we hypothesized that AR and PKA activation play a negative modulatory role in PKD activation in adult
myocytes.
To test this concept, we first investigated the effects of -AR and PKA
activation on PKD translocation in adult cardiac myocytes since classic PKD
activation is characterized by its initial sarcolemmal translocation followed by its
nuclear translocation (Rozengurt et al., 2005; Wang, 2006). To study intracellular
PKD translocation, we cultured adult rabbit myocytes with GFP-tagged PKD1
adenovirus overnight to observe its translocation in response to ISO or forskolin
treatment. Results in figure 49 show that ISO or forskolin treatment did not
induce any baseline PKD translocation to the sarcolemma. This is opposite to
what we had previously observed for ET-1 and PE induced response (Bossuyt et
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al., 2011). Notably, we did detect a minor recruitment of PKD to the nucleus
(Figure 50) in response to ISO and forskolin. This is unexpected since we and
others have reported that PKD nuclear import usually follows its sarcolemmal
translocation under Gq-agonist stimulation (Bossuyt et al., 2011). However, since
PKD has been reported to participate in AKAP complexes (Carnegie et al., 2004;
Carnegie et al., 2008), it is possible that PKA at that locus could preferentially
phosphorylate PKD without the normal sarcolemma recruitment. This suggests
that -AR/PKA activation mediates nuclear import of PKD independent of its
translocation to the sarcolemma, where PKD can be activated by upstream novel
PKC isoforms during the canonical PKD activation pathway (Rey et al., 2004;
Rey et al., 2001; Waldron and Rozengurt, 2003; Wang, 2006).
Since -AR and PKA activation did not drive PKD translocation to the
sarcolemma, we postulated that pre-stimulation of -AR will block the Gqmediated PKD translocation in adult myocytes. Figure 51 shows that the
prominent sarcolemmal translocation under ET-1 stimulation was effectively
blocked with ISO pretreatment, suggesting a negative regulation by -AR
activation of the Gq-induced PKD translocation. Indeed, ISO pretreatment
markedly diminished the ET-1 and PE induced PKD translocation to the
sarcolemma (Figure 52). In parallel, Gq-agonist mediated nuclear import of PKD
was also significantly reduced by pre-incubation of ISO (Figure 53). This could be
partially explained by the fact that basal ISO-induced PKD translocation to the
nucleus already occurs (Figure 50), thus we did not observe further increase in
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PKD nuclear translocation upon ET-1 or PE treatment. These findings suggest
that the sequential pattern of PKD translocation to the sarcolemma followed by
the nuclear recruitment under Gq-agonist stimulation is altered by -AR or PKA
activation.
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Figure 49. -AR or PKA activation induced negligible sarcolemmal PKD1GFP translocation in adult myocytes. Top: Representative confocal image of
ISO-induced PKD1-GFP translocation before and after 1 hr treatment. Bottom:
Isolated adult rabbit myocytes with PKD1-GFP overexpression were treated with
ISO (100 nM) or forskolin (10 M) for 1 hr.
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Figure 50. -AR or PKA activation mediated minor PKD1-GFP nuclear
translocation in adult myocytes. Isolated adult rabbit myocytes with PKD1GFP overexpression were treated with ISO (100 nM) or forskolin (10 M) for 1 hr.
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Figure 51. Confocal images of PKD1-GFP in response to ET-1 alone or with
-AR pre-stimulation. Cultured adult myocytes were treated with ET-1 (100 nM)
alone or pretreated with ISO (100 nM) for 20 min.
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Figure 52. Effects of -AR pre-stimulation on Gq-agonist induced PKD1GFP translocation to the sarcolemma. Isolated adult rabbit myocytes were
treated with ET-1 (100 nM) or PE (20 M) alone for 1 hr or pretreated with ISO
(100 nM) for 20 min.
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Figure 53. -AR pre-stimulation negatively modulates Gq-agonist induced
PKD1-GFP translocation to the nucleus. Isolated adult rabbit myocytes were
treated with ET-1 (100 nM) or PE (20 M) alone for 1 hr or pretreated with ISO
(100 nM) for 20 min.

-AR and PKA activation display minor nuclear PKD activation
Our

previously

publication

reports

that

compartmentalized
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PKD

translocation is associated with its local activation (Bossuyt et al., 2011). Since
our data indicated a negative modulatory role of -AR/PKA activation on Gqmediated PKD translocation, we postulated that consequently, local PKD
activation can also be negatively regulated by -AR and PKA stimulation. We
tested our hypothesis by overexpressing targeted DKAR constructs in cultured
adult myocytes to examine PKD activation at the plasma membrane and the
nucleus (measured with DKAR-SL and DKAR-Nuc respectively). These FRETbased biosensors produce a decrease in FRET signal due to a conformational
change between the CFP and YFP once active PKD phosphorylates its pseudosubstrate (see Figure 13) (Kunkel et al., 2007).
ISO or forskolin treatment alone did not trigger PKD activation at the
sarcolemma since we did not observe any PKD activity measured with DKAR-SL
(Figure 54). However, consistent with our confocal translocation data in figure 50,
we did observe a minor PKD activation signal in the nucleus upon forskolin
treatment, but not upon ISO stimulation (Figure 55). These findings imply that
basal PKA activation can independently trigger PKD translocation to the nucleus
where PKD can be activated without inducing its initial translocation to the
sarcolemma. Moreover, ET-1 or PE induced PKD activity at the plasma
membrane and the nucleus were both reduced by ISO pretreatment (Figure 56
and Figure 57). The data are consistent our hypothesis that -AR or PKA
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activation negatively regulates the Gq-agonist-induced PKD activation in adult
myocytes.
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Figure 54. -AR and PKA activation do not trigger basal sarcolemmal PKD
activity. Isolated adult myocytes overexpressing DKAR-SL were treated with
ISO (100 nM) or forskolin (10 M).
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Figure 55. PKA activation triggers nuclear PKD activation. Isolated adult
myocytes overexpressing DKAR-Nuc were treated with ISO (100 nM) or forskolin
(10 M).
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Figure 56. -AR pre-stimulation reduces PKD activation by ET-1 and PE at
the sarcolemma. Isolated adult myocytes overexpressing DKAR-SL were
pretreated with ISO (100 nM) for 20 min followed by either ET-1 (100 nM) or PE
(20 M) treatment for 30 min.
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Figure 57. -AR pre-stimulation reduces PKD activation by ET-1 and PE in
the nucleus. Isolated adult myocytes overexpressing DKAR-Nuc were
pretreated with ISO (100 nM) for 20 min followed by either ET-1 (100 nM) or PE
(20 M) treatment for 30 min.

-AR and PKA stimulation reduces PKD activation at its
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S916

autophosphorylation site
PKD contains an autophosphorylation site at S916, which is often used as
biochemical readout of its activity. Thus, we examined whether endogenous PKD
S916 phosphorylation was altered in response to -AR or PKA activation.
Isolated adult rat myocytes were treated with Gq-agonist, ET-1 and PE, or with
ISO and forskolin to compare any difference in PKD activation in response to Gq
and -AR signaling. PdBu, a phorbol ester that directly induces maximal PKD
activation without Gq-coupling is used as a positive control. Figure 58 shows that
hypertrophic agonist, ET-1, PE and PdBu all triggered significant S916
phosphorylation of PKD in adult rat myocytes while ISO and forskolin resulted in
reduced PKD activation at S916 compared to control.
In addition, 20 min pretreatment with forskolin markedly decreased the
ET-1 and PE mediated S916 phosphorylation. This indicates that PKA activation
effectively prevents the subsequent Gq-induced PKD activation at S916 site.
S916 phosphorylation of PKD in response to PdBu was not affected by PKA
activation because phorbol ester can activate PKD directly, bypassing the Gqcoupled intracellular signaling.
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Figure 58. Endogenous PKD S916 phosphorylation in response to Gq or AR/PKA activation. Isolated adult rat myocytes were treated with indicated
agonist alone for 20 min or with pretreatment of forskolin for 20 min (ET-1 = 100
nM, PE = 20 M, PdBu = 200 nM, ISO = 100 nM and forskolin = 10 M). We
probed for endogenous PKD S916 phosphorylation. *p<0.05. (n = 3).

Mechanism of -AR/PKA modulation of Gq-induced PKD activation
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In silico analysis of PKD sequence reveals that there exists a potential
PKA phosphorylation site at serine 427 (S427). To further dissect the mechanism
of -AR/PKA modulation of Gq-induced PKD activation, we aim to create a nonphosphorylatable and a phosphomimetic mutant of PKD at this site by replacing
the serine with an alanine (S427A) and a glutamate (S427E) respectively. We
have finished making the adenoviral DNA for these two mutations and plan to
amplify the mature adenovirus for the following experiments.
We will test our hypothesis that PKA modulation of Gq-induced PKD
activation is mediated via PKA phosphorylation at S427 site. If our hypothesis
was correct, we anticipate that the non-phosphorylatable mutant will abolish the
negative PKA effect on PKD translocation and activation in response to ET-1 and
PE. In other words, pretreatment of ISO or forskolin should not alter the Gqagonist mediated translocation of GFP-tagged PKD-S427A mutant to the
sarcolemma and to the nucleus. In addition, ISO or forskolin pretreatment should
not affect the Gq-agonist induced PKD activation.
However, we cannot assess PKD activation using the targeted DKAR
biosensors because we will need to co-infect with the mutant PKD-S427A with
the DKAR construct. Therefore, we plan to culture adult myocytes with GFPtagged WT-PKD or PKD-S427A mutant and treat them with ET-1 or PE alone
and with pretreatment of ISO or forskolin. We will then immunoprecipitate the
protein using the GFP antibody to probe for PKD S916 phosphorylation between
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the WT PKD and the mutants. If the negative modulation of -AR/PKA is
mediated via S427 phosphorylation, then we anticipate to observe a decrease in
PKD S916 phosphorylation in WT PKD when pretreated with ISO or forskolin
followed by Gq-agonist exposure. Conversely, the downregulation of PKD S916
phosphorylation by -AR/PKA activation should be abolished in the PKD-S427A
sample due to the unavailability of PKA phosphorylation site.
Parallel to the experiments above, the phosphomimetic PKD-S427E
mutant should mimic the PKA phosphorylation at S427 site. We anticipate that
the baseline PKD-S427E localization will exhibit slightly higher nuclear
localization compared to WT PKD (mimicking our observation in Figure 55 with
ISO and forskolin treatment). We will compare the translocation of this mutant to
the WT PKD in response to ET-1 and PE treatment alone. If S427 is the PKA
modulatory site, then PKD-S427E mutant will block the ET-1 and PE mediated
PKD translocation to the sarcolemma and the nucleus as if it was stimulated with
ISO or forskolin. Similarly, we will determine the S916 phosphorylation level in
myocytes cultured with WT PKD or PKD-S427E variant. The PKD-S427E variant
represents a condition where PKA phosphorylation of PKD at S427 was present,
and it should exhibit decreased sarcolemmal and nuclear translocation in
response to ET-1 or PE treatment alone.
In

addition

to

probing

PKD

S916

phosphorylation

using

immunoprecipitation, an alternative approach to detect PKD activity is to perform
co-immunoprecipitation (co-IP) of GFP-tagged WT PKD, PKD-S427A and PKD-
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S427E from cultured adult myocytes. We will then determine the corresponding
PKD activity in the co-IP samples by using a PKD substrate specific phosphoantibody. In parallel, we will also probe for overall PKA phosphorylation levels on
PKD by using two different PKA substrate phospho-antibodies. This could
provide information as to whether the S427 residue is important for the
interaction between PKA and PKD if phosphorylation status itself did not alter the
PKD translocation in adult ventricular myocytes.
Alternatively, to investigate whether -AR/PKA activation drastically alters
the binding protein partners for PKD, we can also examine any difference in the
associated proteins in a co-IP experiment with or without ISO and forskolin
presence. We will cultured the isolated adult myocytes with WT PKD1-GFP and
treat them with Gq-agonist alone or pretreat with ISO or forskolin. We will then
process the samples to be run on an SDS-PAGE gel and stain with Commassie
to detect any visible difference in protein patterns. We plan to determine the
molecular identity of any major differential bands between the treatments using
proteomics approach. This approach may be an optimal way of discerning
changes in PKD association with other proteins via scaffolding complex (e.g
AKAP) or microdomain network.
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Discussion
This study highlights the PKA modulation on spatiotemporal PKD
translocation and activation in adult cardiac myocytes. We do not observe any
sarcolemmal PKD translocation upon -AR and PKA activation, and only minor
PKD nuclear recruitment. This is different from the spatiotemporal PKD activation
in response to ET-1 and PE which trigger discernible sarcolemma and nuclear
PKD mobilization (Bossuyt et al., 2011). Furthermore, pre-activation of -AR and
PKA significantly reduces the following ET-1 and PE mediated PKD translocation
and activation compared to Gq-agnoist treatment alone. Although the molecular
mechanism of such negative PKA modulation on PKD translocation and
activation remains to be elucidated, our findings represent an important crosstalk
interaction between PKA and PKD signaling pathways in adult myocytes. In
particular, our data provide further understanding of heart failure, which is
associated with a reduced -AR/PKA signaling and increased PKD activity.
The functional role of PKD to regulate cardiac disease has been
established due to its association with MEF2-dependent transcriptional activation
during hypertrophy. In particular, PKD has been reported to be a HDAC5 kinase
that mediates the phosphorylation of this transcriptional repressor during its
phosphorylation-dependent nuclear export (Bossuyt et al., 2008; Harrison et al.,
2010; Harrison et al., 2006; McKinsey, 2011). Activation of PKD is therefore
tightly linked to the initiation of “fetal gene program” via its effect to mediate
HDAC5 nuclear export, thus relieving the transcriptional inhibition in adult cardiac
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myocytes. While we and others report that PKD can be activated in response to
neurohumoral stimuli, the interaction of PKD signaling pathway with -AR/PKA
activation remains unclear, especially in adult cardiac myocytes.
Our study examines the direct effect of -AR/PKA activation on real-time
PKD translocation and activation for the first time in adult myocytes. Intracellular
PKD activation typically correlates with its translocation upon agonist stimulation.
We report that -AR and PKA activation do not trigger any PKD translocation to
the sarcolemma, where PKD can be activated by novel PKC phosphorylation
(Rey et al., 2004; Rey et al., 2001; Waldron and Rozengurt, 2003; Wang, 2006).
In addition, PKD translocation and activation in response to ET-1 and PE
treatment are both attenuated by pretreatment with ISO and forskolin. The data
indicate that -AR/PKA activation plays a negative regulatory role in Gqmediated PKD translocation and activation.
Although we do not yet understand the mechanism of how PKA activity
negatively regulates PKD activation, we speculate this modulation perhaps
occurs proximally to Gq activation. Gq-agonist stimulation is known to couple
with PLC activation to produce intracellular IP3 and DAG, which can trigger
downstream activation of classical and novel PKC isoforms. Our immunoblot
data show that Gq-agonist activation of PKD is effectively reduced by preincubation of forskolin while PdBu-induced PKD activation is not altered. Since
PdBu is a phorbol ester that can directly activate PKD, we speculate that PKA
modulation of PKD activation is dependent on Gq-activation and may occur
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upstream of PKD.
For example, previous work by Haworth et al. demonstrated that PKA and
PKC have counter-regulatory roles in PKD activation in response to ET-1
(Haworth et al., 2007). PKC is identified as the major PKC isoform to facilitate
PKD activation, and its effect can be negated by ISO and forskolin pretreatment.
This suggests that the acute -AR/PKA activation dominates the effect of PKC
activation in cardiac myocytes to prevent PKD activation. Their following report in
2011 indicates that basal activity of PDE3 and PDE4 keep PKA activity low, and
their combined inhibition is sufficient to mimic PKA activation by forskolin, thus
blocking ET-1-induced PKD activation (Haworth et al., 2011). However, the
molecular details of PKA countering the functional role of PKC regulation of
PKD activation remain unknown.
Alternatively, there is a potential PKA phosphorylation site within PKD
sequence at S427. We propose to mutate this serine to alanine or glutamate to
test the hypothesis that PKA can directly phosphorylate PKD, and this
phosphorylation negatively regulates the Gq-induced PKD activation. The S427
residue is located right before the PH domain of PKD. Since the PH domain in
general is known to mediate binding of intracellular proteins to phosphoinositol
phospholipids (Liao and Hung, 2010; Mashanov et al., 2004), we postulate that
PKA phosphorylation at S427 site could alter the potential PKD interaction with
membrane phospholipids via allosteric hindrance. The canonical PKD activation
pathway requires concomitant PKD translocation with PKC toward the plasma
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membrane. Any allosteric hindrance of PKD binding to membrane phospholipids
will perhaps reduce its translocation and consequently negatively affect its
activation.

Our

future

experiments

with

the

non-phosphorylatable

and

phosphomimetic mutants will help us delineate the mechanism of PKA
modulation on PKD translocation and activation.
In addition, we cannot exclude the possibility that PKA activation can
mediate PKD nuclear translocation and activity without directing its translocation
to the sarcolemma. For instance, there are studies supporting the association of
PKA with PKD via AKAP-Lbc in myocytes (Carnegie et al., 2004; Carnegie et al.,
2008). The pool of PKD within this scaffolding complex could be positioned near
PKA at baseline and could translocate to different intracellular compartments,
such as the nucleus or Golgi, upon PKA activation. Alternatively, PKA-dependent
phosphorylation of PKD could drive it toward a different signaling pathway,
making it less available for its classical nuclear HDAC5 kinase activity. Further
studies will be required to explore the alternative pathway for PKA-mediated PKD
translocation and function in cardiac myocytes.
Collectively, our findings indicate a crosstalk interaction between PKA and
PKD signaling in adult myocytes. Although the molecular mechanism remains to
be clarified, our results provide useful understanding of cardiac pathophysiology.
For instance, downregulation and desensitization of -AR response and PKA
activity in failing hearts can reduce the PKA suppression of PKD activity triggered
by neurohumoral stress. Consequently, PKD may be hyper-active contributing to
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progressive cardiac dysfunction. Therefore, insights to PKA regulation of PKD
activity can shape the therapeutic designs in the future for heart failure treatment.

CHAPTER 7
CONCLUSION
My dissertation research highlights the importance of two major
transducers of extrinsic stress stimuli in adult cardiac myocytes. Both PKD and
HDAC5 are attractive therapeutic targets for future cardiovascular drug
development due to their implications in cardiac epigenetic regulation. The heart
has the unique properties to adapt to biochemical stress by triggering growth in
the terminally differentiated cardiac myocytes. The hypertrophic response can be
initiated with nuclear export of HDAC5. As a transcriptional repressor, HDAC5
localization and translocation are critical to its functional role as an epigenetic
regulator. The shuttling of HDAC5 between the nucleus and the cytosol occurs
dynamically and can be modulated by neurohumoral stress. PKD, along with
CaMKII, has emerged as key HDAC kinase that mediates its phosphorylationdependent shuttling. PKD has become a translational interest for cardiovascular
drug development since the discovery of its regulatory role in hypertrophic
signaling and heart failure.
My work examines the spatiotemporal activation of PKD in isolated adult
cardiac myocytes, and how its activation triggers consequent transcriptional
activation via HDAC5 nuclear export. Our findings indicate that ET-1 and PE
180
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differentially activate PKD, yet converge at the level of HDAC5 shuttling to trigger
hypertrophic signaling in adult myocytes. Hemodynamic stress can often induce
activation of both -AR and Gq-receptors, thus I also explore the crosstalks
between the Gq and -AR signaling pathways regarding their effects on the
transcriptional control via HDAC5. The data suggest that acute -AR signaling
via PKA is protective against the Gq-driven transcriptional activation by
promoting nuclear accumulation of HDAC5. Furthermore, chronic (24-hour) PKA
activation now permits HDAC5 nuclear export in response to Gq-agonist, ET-1
and PE. The contrasting effects of acute vs chronic -AR/PKA signaling on
transcriptional activation triggered by neurohumoral stimuli represent an
important

regulation

in

cardiac

pathophysiology.

This

mechanism

of

transcriptional control is pertinent to exercise or fight-or-flight response where
acute sympathetic signaling demands increased cardiac output without triggering
maladaptive changes.
Consequently, I postulate a role for PKA modulation in PKD activation and
may act as an additional mechanism by which PKA signaling prevents nuclear
export of HDAC5 in adult cardiac myocytes. Preliminary data demonstrate that
PKA activation alters the classical PKD translocation to the sarcolemma with
minor nuclear PKD transblocation and activity. While the molecular mechanism
remains to be further investigated, the cross interaction between PKA and PKD
signaling could have a huge impact on understanding heart failure, where PKA
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and -AR responses are downregulated while PKD expression and activity are
increased.
While the cardiac remodeling is a complex process and has many
contributing factors, our research has established a critical role for hypertrophic
signaling pathway mediated by the activation of PKD and the consequent
HDAC5 shuttling in adult myocytes.
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